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Abstract  
Activated Leukocyte Cell Adhesion Molecule (ALCAM) is expressed at the surface of epithelial 
ovarian cancer (EOC) cells and is released in a soluble form (sALCAM) by ADAM-17-mediated 
shedding. This process is relevant to EOC cell motility and invasiveness, which is reduced by 
inhibitors of ADAM-17. In addition, ADAM-17 plays a key role in EGFR signalling and thus may 
represent a useful target in anticancer therapy. Herein we report our hit optimization effort to 
identify potent and selective ADAM-17 inhibitors, starting with previously identified inhibitor 1. A 
new series of secondary sulfonamido-based hydroxamates was designed and synthesized. The 
biological activity of the newly synthesized compounds was tested in vitro on isolated enzymes and 
human EOC cell lines. The optimization process led to compound 21, which showed an IC50 of 1.9 
nM on ADAM-17 with greatly increased selectivity. This compound maintained good inhibitory 
properties on sALCAM shedding in several in vitro assays.  
 
1. Introduction  
ADAM-17 or Tumor Necrosis Factor-α Converting Enzyme (TACE) is an integral plasma 
membrane zinc-dependent metalloprotease and member of the A Disintegrin And Metalloprotease 
(ADAM) family of molecules. ADAM-17 is produced as an inactive proenzyme of 120 kDa, which 
is physiologically activated via stimulation of G protein–coupled receptors and furin-like enzyme 
cleavage of the ADAM-17 prodomain leading to generation of the 100 kDa active enzyme. ADAM-
17 is a sheddase and/or activator of several biologically important membrane-anchored proteins, 
including TNF, epithelial cell growth factors, and cell adhesion molecules.1 In recent years, we 
focused our attention on studying interaction between ADAM-17 and cell adhesion molecules 
(CAMs) of the immunoglobulin superfamily. In particular, we have shown that Activated 
Leukocyte Cell Adhesion Molecule (ALCAM or CD166) is expressed at the surface of epithelial 
ovarian cancer (EOC) cells, can be internalized following soluble ligand engagement2 and is 
released in a soluble form (sALCAM) by ADAM-17-mediated shedding.3 This process is relevant 
to EOC cell motility, which is reduced by inhibitors of ADAM-17. In addition, ADAM-17 plays a 
key role in Epidermal Growth Factor Receptor (EGFR) signalling4 and thus may represent a useful 
target in anticancer therapy in EGF-dependent tumours.5 Recently, we have reported the synthesis 
and biological evaluation of a series of arylsulfonamide hydroxamates as potent ADAM-17 
inhibitors.6 Among these, compound 1 (Figure 1) showed a nanomolar activity for ADAM-17 
isolated enzyme. This compound proved to be also potent in inhibiting soluble ALCAM release in 
cancer cells, showing a nanomolar activity on A2774 and SKOV3 cell lines. No toxicity for this 
compound was detected on parallel cultures by MTT assay. In addition, it inhibited the EGF-
triggered invasive properties of ovarian cancer cells in vitro.7 These preliminary results allowed us 
to validate ADAM-17/ALCAM pathway as new target in anticancer therapy and prompted us to 
undertake a structural optimization of 1 in order to find out more selective ADAM-17 inhibitors. In 
fact, compound 1 also inhibited other metalloproteases such as MMP-2, MMP-9 and MMP-14 and 
it is widely believed that some side effects that have been clinically observed with the use of broad 
spectrum MMP inhibitors, such as musculoskeletal syndrome (MSS), could be related to MMP-
1/MMP-14 inhibition.8 Moreover, a more target-directed inhibition could be helpful to discern the 
actual ADAM-17 biological activity from overlapping effects due to other metalloproteases and to 
reduce toxicity.  
 
FIGURE 1 HERE 
 
In the present paper, based on recent SAR data from our lab and others,9 we designed and 
synthesized a series of secondary sulfonamido-based inhibitors, compounds 2-1310 (Table 1), with 
bended P1’ substituents different from the highly exploited 4-(but-2-ynyloxy)benzene group. In 
fact, as revealed by X-ray crystal structure of catalytic domain11, ADAM-17 is characterized by an 
“L-shaped” pocket with a polar access between S1’ and S3’, and this singular shape of the 
specificity pocket has been largely used to design specific ADAM-17 inhibitors by insertion of 
bended substituents. Two examples of these selective inhibitors reported in literature for the 
treatment of inflammatory diseases are DPC-33312 from Bristol-Myers Squibb (which entered 
clinical trials for rheumatoid arthritis) and WAY-281418,13 developed by Wyeth researchers (Figure 
2).  
 
FIGURE 2 HERE 
 Hydroxamates 2-13 were screened against recombinant human ADAM-17 in order to select the P1’ 
substituent able to give the best results of selectivity for ADAM-17 over MMPs. After the most 
suitable and innovative P1’ substituent has been found, we sought to improve activity against 
ADAM-17 by introducing an amidic chain in the α position relative to the hydroxamate (P1), 
compounds 19-2110 (Table 3). In fact, as previously shown,6 an α substituent in this 
arylsulfonamidic scaffold could highly increase potency against ADAM-17. The compounds which 
gave the best results on isolated enzymes were finally tested on human EOC cell lines (A2774, 
SKOV3-luc and A2780), which express ADAM-17 and its substrate ALCAM. 
 
2. Chemistry. 
Compound 2 (Table 1) has been synthesized as previously described.14 Benzyloxy-benzene 
derivatives 3-13 (Table 1) and 16 (Table 2) have been prepared as reported in Scheme 1. 
 
SCHEME 1 HERE 
 
Sulfonyl chlorides 33-43 were synthesized starting from sodium 4-hydroxybenzenesulfonate 
dihydrate, which was alkylated with the appropriate aryl bromides using sodium hydroxide as base. 
Reaction of sodium salts 22-32 with oxalyl chloride in the presence of DMF in dichloromethane 
afforded sulfonyl chlorides 33-43, which were coupled with glycine to give carboxylic acids 44-53 
and 16. Carboxylates 44-46 and 49-53 were condensed with O-(tert-
butyldimethylsilyl)hydroxylamine in presence of 1-[3-(Dimethylamino)propyl]-3-ethyl 
carbodiimide hydrochloride (EDC) to give silyl intermediates 54-61, which afforded hydroxamates 
3-5 and 8-12 after acid cleavage with TFA. Alternatively, carboxylates 47, 48 and 16 were first 
converted into protected hydroxamates 62-64 by condensation with O-(tetrahydro-2H-pyran-2-
yl)hydroxylamine (THP-hydroxylamine) in the presence of EDC and then hydrolyzed with 4 N HCl 
to hydroxamates 6, 7 and 13, respectively. 
Compounds 17 and 18 (Table 2), close analogues of 13, were synthesized according to the route 
described in Scheme 2. 4-(3,5-Dibromobenzyloxy)benzene-1-sulfonyl chloride 43 was converted 
into the sulfonamide 65 by reaction with glycine tert-butyl ester hydrochloride in H2O and dioxane 
in the presence of TEA. This ester was successively converted by Pd-catalyzed Suzuki coupling to 
mono-substituted biaryl derivatives 66 and 67, which were hydrolyzed to carboxylic acids 68 and 
69 respectively. These carboxylates were finally converted to their corresponding hydroxamates 17 
and 18 by condensation with O-(tert-butyldimethylsilyl)hydroxylamine, followed by acid 
hydrolysis with TFA. 
 
SCHEME 2 HERE 
 
N-Methyl derivative 15 (Table 2) and the α-substituted analogues of 13, compounds 19-21 (Table 
3), were prepared as reported in Scheme 3. All these compounds were synthesized starting from 4-
(3,5-Dibromobenzyloxy)benzene-1-sulfonyl chloride 43, obtained as described above. 43 was 
converted into the corresponding Boc-sulfonamide 76 by reaction with ammonia, followed by 
treatment with di-(tert-butyl)dicarbonate. Sulfonamide 76 underwent Mitsunobu reaction in the 
presence of diisopropylazodicarboxylate (DIAD) and triphenylphophine with optically active 
alcohol 776 to give ester 78 of (R) configuration. Acid hydrolysis of 78 yielded the NH-sulfonamide 
carboxylate 79, which was finally converted into the corresponding hydroxamate 19 by 
condensation with THP-hydroxylamine in DMF and acid cleavage with 4 N HCl. The sulfonyl 
chloride 43 was also made reacting with non-natural aminoacids such as sarcosine tert-butyl ester 
hydrochloride or D-Cbz-ornithine or D-carbamoyl-ornithine in the presence of TEA to give 
sulfonamides 70, 72 and 73, respectively. Acid hydrolysis with TFA of tert-butyl ester 70 afforded 
carboxylate 71. Condensation of 71 and 72 with THP-hydroxylamine in the presence of EDC 
yielded tetrahydropyranyl intermediates 74 and 75 which, after mild hydrolysis with HCl 4N, gave 
the corresponding hydroxamates 15 and 20. Finally, hydroxamic acid 21 was obtained from 
carboxylate 73 by condensation with O-(tert-butyldimethylsilyl)hydroxylamine, followed by acid 
hydrolysis with TFA. 
 
SCHEME 3 HERE 
 
3. Results and Discussion 
Biological Activity on Isolated Enzymes. 
The first series of hydroxamates, compounds 2-13, were tested in vitro for their ability to inhibit 
human recombinant ADAM-17, MMP-1, -2, -9 and -14 by a fluorimetric assay, which uses a 
fluorogenic peptide15 as the substrate (Table 1). Compound 1416, previously reported by Wyeth 
researchers as ADAM-17 inhibitor and bearing the highly exploited 4-(but-2-ynyloxy)benzene 
group in P1’, was taken as reference compound to evaluate the effect of the different R groups on 
the simple glycine-like scaffold. On the basis of our previous results6, we focused our attention on 
secondary sulfonamides because the substitution of sulfonamide NH was seen to be detrimental to 
ADAM-17 inhibitory activity.  
Among the substituted benzyloxy derivatives, the best results of activity were achieved by 
compound 3, which resulted as potent as the reference compound 14 on ADAM-17 (IC50=16 nM). 
Unfortunately, this 4-bromobenzyloxy derivative was poorly selective, showing nanomolar activity 
also against MMP-2 and MMP-9. The replacement of the bromine atom with a fluorine or a 
trifluoromethoxy group in the para-position led to a drop of activity for ADAM-17, with the 4-
phenyl derivative 6 being the worst of the series (IC50=640 nM). The introduction of the same 
substituents in the meta-position of the benzyl moiety resulted in a general improvement of ADAM-
17 inhibitory activity with respect to the unsubstituted analogue 2, without any significant 
improvement in selectivity. Finally, the presence of a 4-quinoline group as in 11 led to a decrease of 
activity against all tested enzymes, probably due to an excessive bulkiness of the substituent.  
At this point the introduction of a second halogen atom on the benzyl moiety was considered and 
the 3,5-di-halo substituted compounds 12 and 13 were synthesized. Both compounds had the same 
activity towards ADAM-17 with respect to their 3-mono substituted analogues (7 and 8) but 
presented an increased selectivity over the MMPs tested. In particular, the 3,5-dibromobenzyloxy 
derivative 13 resulted the most promising of this first series, with a good activity for ADAM-17 
(IC50=105 nM) and the best selectivity profile obtained so far over MMPs (a > 500-fold selectivity 
over MMP-9, -14 and -1), even compared to the reference compound 14. These data suggested that 
the 3,5-dibromobenzyloxybenzene group could be a valid alternative to the use of the 4-(but-2-
ynyloxy)benzene group as P1’ substituent, and therefore 13 became the focus of additional efforts 
to improve activity towards ADAM-17.  
 
TABLE 1 HERE 
 
Compounds 15-18 (Table 2) were subsequently synthesized as close analogues of 13, introducing 
some modifications on this promising scaffold. We first synthesized the N-methyl analogue of 13 
(15), which showed a decrease of ADAM-17 inhibitory activity compared to 13. Then we tested the 
carboxylate analogue of 13, compound 16, in order to evaluate the effect of a different zinc-binding 
group (ZBG) on this scaffold but this compound was completely devoid of activity for ADAM-17. 
This disappointing result discouraged us to change the ZBG at least at this point of the optimization 
process. Finally, we replaced a bromine atom of 13 with a pyridin-3-yl moiety (18) or a 4-
methoxyphenyl group (17) in order to better explore the S1’-S3’ pocket space. Both compounds 
showed a reduced inhibitory activity against ADAM-17, with 18 being 5-fold less active than 13.  
 
TABLE 2 HERE 
 On the basis of these findings, in order to further increase activity on ADAM-17 of this class of 
inhibitors, we decided to keep the compound 13 scaffold unchanged and to introduce different 
amidic chains in P1. In fact, as previously shown,6 an α substituent in this arylsulfonamidic scaffold 
could highly increase potency against ADAM-17. First, we chose to insert a 
benzyloxycarbonylamino-ethyl chain in P1 because this was the group originally present in our 
previous compound 1. As expected, compound 19 (Table 3) resulted 2.5-fold more active than its 
unsubstituted analogue 13, showing an IC50=43 nM on ADAM-17, without any loss in selectivity. 
Encouraged by this data, we put a longer chain in P1 and synthesized compound 20 (Table 3) with a 
benzyloxycarbonylamino-propyl chain. We thus obtained a further increase of ADAM-17 inhibitory 
potency (IC50=11 nM) still maintaining a strong selectivity over MMPs, even compared to 19. In 
particular, the selectivity for ADAM-17 over MMP-2 progressively increased from 16-fold for 
compound 13 to 130-fold for 20. Finally, as last step of our optimization process we tried to 
improve the hydrophilicity of our inhibitor by replacing the benzyloxycarbonylamino (Cbz) moiety 
of 20 with an ureidic group (compound 21, Table 3).  
 
TABLE 3 HERE 
 
For 21 and its analogue 20, the physico-chemical properties influencing metabolism, cell 
permeation, and bioavailability were evaluated with QikProp software (Schrödinger, LLC New 
York). As shown in Table 4, while 20 possesses an high MW, high number of H-bond acceptors 
and a logS which is quite far from ideal values, 21 has a lower MW, appropriate number of H-bond 
donors and acceptors, and a good logS. Thus, the replacement of the Cbz moiety in 20 with an 
ureidic group (21) should lead to an improvement of the physico-chemical properties of the 
inhibitor.  
 
TABLE 4 HERE 
 
Unpredictably, this ureidic derivative was optimal for this series exhibiting a 6-fold increase in 
inhibitory potency against ADAM-17 (IC50=1.9 nM) with respect to 20 and a comparable 
selectivity profile. In fact, 21 displayed a 126-fold selectivity for ADAM-17 over MMP-2, a 860-
fold selectivity over MMP-9, a 10000-fold selectivity over MMP-14 and no measurable inhibitory 
activity toward MMP-1 (IC50>500 μM). Table 5 shows a direct comparison between the selectivity 
profiles of 21 and of our previous compound 1. 21 resulted as potent as 1 on ADAM-17 (with an 
IC50=1.9 nM and 1.6, respectively) but showed a greatly improved selectivity over the tested 
MMPs. 
 
TABLE 5 HERE 
 
All these P1-substituted compounds (19-21) and their unsubstituted analogue 13 were also screened 
against human recombinant ADAM-10, which has the highest aminoacid sequence homology as 
compared to ADAM-17 among all known MMPs.17 ADAM-10 is not implicated in ALCAM 
ectodomain shedding but is able to cleave another cell-cell adhesion molecule, desmoglein 2 (Dsg-
2), together with ADAM-17. 18 Moreover, ADAM-10 is considered a target in anticancer therapy 
for its ability to shed the human epidermal growth factor receptor-2 (HER-2), a tyrosine kinase 
receptor that is associated with cancer proliferation.19 Among the tested compounds, 21 was found 
to be the most active on this enzyme, with an IC50=150 nM. 
Biological Activity on Ovarian Cancer Cell Lines. 
The activity of compounds 1, 13, 19-21 was then evaluated in living cancer cells. As described 
before,6 modulation of soluble sALCAM release can be used as read-out test to score the inhibition 
of ADAM-17 activity in cells. Ovarian cancer cells (A2774, SKOV3-luc and A2780) express high 
cell surface levels of ALCAM, which is shed in soluble form constitutively and even more 
following tyrosine kinase receptor (e.g. EGFR) activation. sALCAM can be easily assessed by 
ELISA of cell culture conditioned media.3 When assayed for inhibition of constitutive or EGF-
induced sALCAM release, each compound was tested at 10 µM, 1 µM, 100 nM and 10 nM 
concentrations with overnight incubation. Multiple tyrosine kinase activation can be mimicked by 
treatment with pervanadate (PV), which is a general phosphotyrosine phosphatase inhibitor that 
leads to metalloproteases activation. As controls, cultures treated with the corresponding amounts of 
solvent (DMSO) were used. Cell morphology was monitored by microscopy and cell viability was 
assed on parallel cultures by MTT assay (data not shown), which showed no significant toxic 
effects on cells. As shown in Table 6, among the new derivatives with greatly increased selectivity 
on isolated enzymes, compound 21 maintained good inhibitory properties on sALCAM shedding in 
any condition, displaying a similar IC50 in the nanomolar range when PV was used as stimulus in 
the three cell lines (a representative dose/response experiment is shown in Figure 3). Consistent 
with data obtained on the ADAM-17 isolated enzyme, compounds 1 and 21 showed comparable 
IC50, while compounds 13, 19 and 20 showed higher IC50. Similar results were obtained using EGF 
as stimulus, although the IC50 observed were in general higher. The different sensitivity of PV- 
versus EGF-induced sALCAM release to the compounds studied may reflect the different levels of 
tyrosine phosphorylation achieved with the two stimuli and the resulting levels of ADAM-17 
activation. Indeed, PV behaves as a stronger stimulus, achieved by its broad ability to block 
phosphotyrosine-phosphatases, resulting in a maximal activation of ADAM-17 and sALCAM 
shedding in a short time frame (90 min of test). On the other hand, EGF is a more specific stimulus 
acting on a single TK-receptor, which requires a longer incubation time (18 h), during which 
redundant and ADAM-17-independent mechanisms of shedding may be operative. 
 
TABLE 6 HERE 
 
FIGURE 3 HERE 
 4. Molecular Modeling  
Docking Studies. To get an insight into the binding mode of 21 into the ADAM-17 active site, 
ensemble-docking studies were performed by means of Glide 5.5 program20. Five X-ray structures 
representative for the enzyme flexibility (PDB codes: 2DDF, 2I47, 2OI0, 3EDZ, 3EWJ)6 were used. 
Docking of 21 in the 2DDF and 2I47 structures resulted in poorly ranked and not fully convincing 
poses as the 3,5-dibromobenzyloxy P1’ group did not occupy the S1’ pocket. This is not surprising 
because in these two structures the S1’ loop is in a closed conformation with not enough room to 
permit the allocation of such a bulky moiety. Otherwise, docking of 21 using 2OI0, 3EDZ and 
3EWJ structures converged on similar and more convincing binding poses, where the P1’ 
substituent properly fits in the S1’ cavity. Particularly, as shown in Figure 4 (PDB code 2OI0), the 
hydroxamate group chelates the zinc ion in a bidentate fashion, the phenyl ring stacks with the 
H405 and interacts with V402 and L348 side chains, while the 3,5-dibromobenzyloxy group is well 
inserted in the S1’ pocket where multiple hydrophobic contacts are detected with V434, L401, 
A439, V440, L401, N447 side chains and with E398 β- and γ-carbons. Moreover, one sulfonamide 
oxygen establishes the commonly found bifurcated H-bond with L348 and Gly349 backbone NH. 
The propyl-urea moiety lies along the S1 pocket establishing hydrophobic contacts with the L350 
and V314 side chains, while multiple H-bonds are detected between the two urea NH and T347 
hydroxyl group and between the urea carbonyl oxygen and the K315 side chain. Clearly, all these 
interactions endowed 21 with a low nanomolar inhibitory activity toward ADAM-17. 
 
FIGURE 4 HERE 
 
As regards the activity of 21 towards MMPs, it is well known that differential substitutions on the 
P1’ group can be successfully used to design selective inhibitors for MMPs. Indeed, the analysis of 
the MMPs X-ray structures reveals that the length of the S1’ pocket increases in the following 
order: MMP-1 < MMP-14 < MMP-2 ≈ MMP-9. The SAR herein presented (Table 1) corroborates 
this consideration, in fact the activity on MMP-1 drops abruptly by just introducing a bended P1’ 
group (2), while MMP-14 can tolerate para and meta halogenated phenyl decorations (2, 3, 4, 8, 
12). On the contrary, MMP-9 and -2 are able to allocate almost all the inhibitors synthesized except 
for 13 and its derivatives (15-21). Thus, docking studies of 21 into the aforementioned MMPs were 
performed with the aim to better clarify the structural features responsible for the observed 
inactivity towards these enzymes. Unsurprisingly, as regards MMP-1 and -14 (1HFC21 and 3MA2,22 
respectively), the docking program is incapable to find a pose where the P1’ group is inserted into 
the S1’ pocket, thus leaving the majority of 21 poses largely solvent exposed. Conversely, in the 
lowest energy binding poses of 21 into the active sites of MMP-2 and -9 (3AYU,23 4H3X,24 
respectively), the 3,5-dibromobenzyloxy group fits in the S1’ pocket and the hydroxamate group 
chelates the zinc ion, although the sulfonamide geometry is gravely distorted. However, the bottom 
part of the S1’ pocket of both enzymes is open and solvent exposed, with a predominance of 
hydrophilic residues (T143, T145, K146, N147, R149 and S151 in MMP-2; E132, R140, T142, 
E143 and D150 in MMP-9), consequently, it can be assumed that the large and hydrophobic 3,5-
dibromobenzyloxy moiety is not well tolerated in such a region thus accounting for the higher IC50 
on MMP-2 and -9 found for 21.  
 
5. Conclusions 
Starting with our previously published molecule 1, we carried out a systematic SAR investigation of 
the P1’ substituent in order to find out a moiety different from the highly exploited 4-(but-2-
ynyloxy)benzene group able to improve the selectivity for ADAM-17 over MMPs. Optimization of 
the benzyloxy-phenyl portion led to the identification of the 3,5-dibromobenzyloxy-phenyl group, 
which afforded improved ADAM-17 selectivity (compound 13). Furthermore, introduction of an 
amidic chain in the α position relative to the hydroxamate (P1 group) greatly increased potency 
against ADAM-17 (compounds 19-21). In particular, the ureidic derivative 21 resulted the best of 
the series being as potent as 1 on ADAM-17 (IC50=1.9 nM) and showing a greatly improved 
selectivity over the tested MMPs. In fact, 21 displayed a 126-fold selectivity for ADAM-17 over 
MMP-2, a 860-fold selectivity over MMP-9, a 10000-fold selectivity over MMP-14 and no 
measurable inhibitory activity toward MMP-1 (IC50>500 μM). Finally, the compounds, which 
gave the best results on isolated enzymes (13, 19-21), were tested on human EOC cell lines (A2774, 
SKOV3-luc and A2780), which express ADAM-17 and its substrate ALCAM. 21 maintained good 
inhibitory properties on sALCAM shedding in any condition, displaying a similar IC50 in the 
nanomolar range when PV was used as stimulus in the three cell lines. Consistent with data 
obtained on the ADAM-17 isolated enzyme, compounds 1 and 21 showed comparable IC50 also on 
living cancer cells, suggesting that selective inhibition of ADAM-17 activity might be sufficient to 
block sALCAM release in cells. Further investigations are necessary to assess the effect of the 
improved ADAM-17 selectivity in ovarian cancer models in vivo. 
 
6. Experimental Section 
Chemistry. Melting points were determined on a Kofler hotstage apparatus and are uncorrected. 1H 
and 13C NMR spectra were determined with a Varian Gemini 200 MHz spectrometer. Chemical 
shifts (δ) are reported in parts per million downfield from tetramethylsilane and referenced from 
solvent references. Coupling constants J are reported in hertz; 13C NMR spectra were fully 
decoupled. The following abbreviations are used: singlet (s), doublet (d), triplet (t), double-doublet 
(dd), broad (br) and multiplet (m). Where indicated, the elemental compositions of the compounds 
agreed to within ±0.4% of the calculated value. Chromatographic separations were performed on 
silica gel columns by flash column chromatography (Kieselgel 40, 0.040–0.063 mm; Merck) or 
using ISOLUTE Flash Si II cartridges (Biotage). Reactions were followed by thin-layer 
chromatography (TLC) on Merck aluminum silica gel (60 F254) sheets that were visualized under a 
UV lamp and hydroxamic acids were visualized with FeCl3 aqueous solution. Evaporation was 
performed in vacuo (rotating evaporator). Sodium sulfate was always used as the drying agent. D-
Cbz-ornithine (H-D-Orn(Z)-OH) and D-carbamoyl-ornithine (H-D-Cit-OH) were purchased from 
Bachem (Switzerland). 3,5-Dibromobenzyl bromide and 4-bromomethylbiphenyl were purchased 
from ABCR (Germany). 1-(bromomethyl)-3-(trifluoromethoxy)benzene, 1-(bromomethyl)-4-
fluorobenzene, 1-(bromomethyl)-4-(trifluoromethoxy)benzene, 1-(bromomethyl)-3,5-
difluorobenzene, and 8-(bromomethyl)quinoline were purchased from Maybridge (UK). All other 
commercially available chemicals were purchased from Sigma-Aldrich. 
The purity of the final compounds was determined by reverse-phase HPLC on a Merck Hitachi D-
7000 liquid chromatograph. HPLC purity was determined to be >95% for all final products using a 
Discovery C18 column (250 mm × 4.6 mm, 5 μm, Supelco), with a mobile phase of 40% 
water/60% methanol at a flow rate of 1.4 mL/min, with UV monitoring at the fixed wavelength of 
256 nm. See the Supporting Information for compound purity analysis data for final compounds.  
General procedure for the synthesis of benzyloxy-benzene sodium salts 22-32. To a suspension 
of sodium 4-hydroxybenzenesulfonate dihydrate (1.3 g, 5.6 mmol) in isopropanol (25 mL), 
containing 5.6 mL of NaOH 1N freshly prepared, the appropriate substituted benzylbromide (11.2 
mmol) was added. The reaction was refluxed (70 °C) overnight. Isopropanol was evaporated and 
the precipitate was collected by filtration and washed with isopropanol. The solid was dried in 
vacuo. 
Sodium 4-(4-bromobenzyloxy)benzenesulfonate (22). The title compound was prepared from 4-
bromobenzyl bromide following the general procedure. White solid (79% yield). 1H-NMR (DMSO-
d6) δ: 5.10 (s, 2H); 7.38-7.42 (m, 4H); 7.49-7.60 (m, 4H). 
Sodium 4-(4-fluorobenzyloxy)benzenesulfonate (23). The title compound was prepared from 1-
(bromomethyl)-4-fluorobenzene following the general procedure. White solid (74% yield). 1H-
NMR (DMSO-d6) δ: 5.08 (s, 2H); 6.90-6.96 (m, 2H); 7.18-7.26 (m, 2H); 7.37-7.52 (m, 4H). 
Sodium 4-(4-(trifluoromethoxy)benzyloxy)benzenesulfonate (24). The title compound was 
prepared from 1-(bromomethyl)-4-(trifluoromethoxy)benzene following the general procedure. 
White solid (69% yield). 1H-NMR (DMSO-d6) δ: 5.14 (s, 2H); 7.36-7.42 (m, 4H); 7.50-7.59 (m, 
4H). 
Sodium 4-(biphenyl-4-ylmethoxy)benzenesulfonate (25). The title compound was prepared from 
4-bromomethylbiphenyl following the general procedure. White solid (70% yield). 1H-NMR 
(DMSO-d6) δ: 5.17 (s, 2H); 6.94-6.98 (m, 2H); 7.38-7.47 (m, 6H); 7.51-7.55 (m, 5H). 
Sodium 4-(3-bromobenzyloxy)benzenesulfonate (26). The title compound was prepared from 1-
bromo-3-(bromomethyl)benzene following the general procedure. White solid (76% yield). 1H-
NMR (DMSO-d6) δ: 5.13 (s, 2H); 6.91-6.96 (m, 2H); 7.35-7.39 (m, 1H); 7.42-7.43 (m, 1H); 7.47-
7.54 (m, 3H); 7.65-7.66 (m, 1H). 
Sodium 4-(3-fluorobenzyloxy)benzenesulfonate (27). The title compound was prepared from 1-
(bromomethyl)-3-fluorobenzene following the general procedure. White solid (65% yield). 1H-
NMR (DMSO-d6) δ: 5.14 (s, 2H); 6.92-6.96 (m, 2H); 7.11-7.20 (m, 1H); 7.26-7.30 (m, 2H); 7.38-
7.46 (m, 1H); 7.50-7.54 (m, 2H). 
Sodium 4-(3-(trifluoromethoxy)benzyloxy)benzenesulfonate (28). The title compound was 
prepared from 1-(bromomethyl)-3-(trifluoromethoxy)benzene following the general procedure. 
White solid (61% yield). 1H-NMR (DMSO-d6) δ: 5.18 (s, 2H); 6.92-6.96 (m, 2H); 7.31-7.34 (m, 
1H); 7.44-7.54 (m, 5H). 
Sodium 4-(biphenyl-3-ylmethoxy)benzenesulfonate (29). The title compound was prepared from 
3-(bromomethyl)biphenyl following the general procedure. White solid (62% yield). 1H-NMR 
(DMSO-d6) δ: 5.19 (s, 2H); 6.95-6.99 (m, 2H); 7.34-7.55 (m, 7H); 7.61-7.74 (m, 4H). 
Sodium 4-(quinolin-8-ylmethoxy)benzenesulfonate (30). The title compound was prepared from 
8-(bromomethyl)quinoline following the general procedure. Yellow solid (80% yield). 1H-NMR 
(MeOD-d6) δ: 5.79 (s, 2H); 7.75-8.16 (m, 5H); 8.88-8.96 (m, 1H); 9.01-9.09 (m, 1H). 
Sodium 4-(3,5-difluorobenzyloxy)benzenesulfonate (31). The title compound was prepared from 
1-(bromomethyl)-3,5-difluorobenzene following the general procedure. White solid (69% yield). 
1H-NMR (DMSO-d6) δ: 5.15 (s, 2H); 6.92-6.96 (m, 2H); 7.15-7.19 (m, 3H); 7.50-7.54 (m, 2H). 
Sodium 4-(3,5-dibromobenzyloxy)benzenesulfonate (32). The title compound was prepared from 
3,5-dibromobenzyl bromide following the general procedure. White solid (84% yield). 1H-NMR 
(DMSO-d6) δ: 5.13 (s, 2H); 6.92-6.96 (m, 2H); 7.50-7.54 (m, 2H); 7.67-7.68 (m, 2H); 7.80-7.81 (m, 
2H). 
General procedure for the synthesis of benzyloxy-benzene sulfonyl chlorides 33-43. To a 0 °C 
solution of oxalyl chloride (1.3 mL, 15.3 mmol) in dry CH2Cl2 (5.1 mL) under Ar atmosphere, 
DMF was added dropwise (1.2 mL, 15.3 mmol) followed by the appropriate benzyloxy-benzene 
sodium salt 22-32 (5.11 mmol). The reaction was stirred at 0 °C for 10 min. and then at rt for 2 
days. The crude was poured into ice and the product was extracted with EtOAc. Organic layers 
were washed with water, dried over Na2SO4 and concentrated in vacuo to give sulfonyl chlorides 
33-43. 
4-(4-Bromobenzyloxy)benzene-1-sulfonyl chloride (33). The title compound was prepared from 
benzyloxy-benzene sodium salt 22 following the general procedure. The crude product was purified 
by flash chromatography (n-hexane/EtOAc 14:1) using a Isolute Flash Si II cartridge to give 33 as a 
white solid (32% yield). 1H-NMR (CDCl3) δ: 5.10 (s, 2H); 7.06-7.10 (m, 2H); 7.26-7.30 (m, 2H); 
7.51-7.55 (m, 2H); 7.94-7.98 (m, 2H). 
4-(4-Fluorobenzyloxy)benzene-1-sulfonyl chloride (34). The title compound was prepared from 
benzyloxy-benzene sodium salt 23 following the general procedure. The crude product was purified 
by flash chromatography (n-hexane/EtOAc 3:1) using a Isolute Flash Si II cartridge to give 34 as a 
white solid (68% yield). 1H-NMR (CDCl3) δ: 5.13 (s, 2H); 7.07-7.15 (m, 4H); 7.37-7.44 (m, 2H); 
7.95-8.02 (m, 2H). 
4-(4-(Trifluoromethoxy)benzyloxy)benzene-1-sulfonyl chloride (35). The title compound was 
prepared from benzyloxy-benzene sodium salt 24 following the general procedure. White solid 
(65% yield). 1H-NMR (CDCl3) δ: 5.17 (s, 2H); 7.09-7.14 (m, 2H); 7.26-7.29 (m, 2H); 7.45-7.49 (m, 
2H); 7.98-8.02 (m, 2H). 
4-(Biphenyl-4-ylmethoxy)benzene-1-sulfonyl chloride (36). The title compound was prepared 
from benzyloxy-benzene sodium salt 25 following the general procedure. White Solid (70% yield). 
1H-NMR (CDCl3) δ: 5.22 (s, 2H); 6.98-7.02 (m, 2H); 7.12-7.16 (m, 2H); 7.37-7.52 (m, 4H); 7.58-
7.67 (m, 3H); 7.93-8.02 (m, 2H).   
4-(3-Bromobenzyloxy)benzene-1-sulfonyl chloride (37). The title compound was prepared from 
benzyloxy-benzene sodium salt 26 following the general procedure. Yellow oil (76% yield). 1H-
NMR (CDCl3) δ: 5.14 (s, 2H); 7.09-7.14 (m, 2H); 7.28-7.37 (m, 2H); 7.49-7.53 (m, 1H); 7.59-7.60 
(m, 1H); 7.97-8.01 (m, 2H).   
4-(3-Fluorobenzyloxy)benzene-1-sulfonyl chloride (38). The title compound was prepared from 
benzyloxy-benzene sodium salt 27 following the general procedure. White solid (92% yield). 1H-
NMR (CDCl3) δ: 5.17 (s, 2H); 6.97-7.25 (m, 5H); 7.34-7.44 (m, 1H); 7.91-8.01 (m, 2H). 
4-(3-(Trifluoromethoxy)benzyloxy)benzene-1-sulfonyl chloride (39). The title compound was 
prepared from benzyloxy-benzene sodium salt 28 following the general procedure. White solid 
(86% yield). 1H-NMR (CDCl3) δ: 5.19 (s, 2H); 7.10-7.14 (m, 2H); 7.22-7.50 (m, 4H); 7.98-8.02 (m, 
2H). 
4-(Biphenyl-3-ylmethoxy)benzene-1-sulfonyl chloride (40). The title compound was prepared 
from benzyloxy-benzene sodium salt 29 following the general procedure. Yellow oil (98% yield). 
1H-NMR (CDCl3) δ: 5.23 (s, 2H); 6.97-7.02 (m, 2H); 7.11-7.17 (m, 2H); 7.37-7.64 (m, 8H); 7.91-
8.01 (m, 2H). 
4-(Quinolin-8-ylmethoxy)benzene-1-sulfonyl chloride (41). The title compound was prepared 
from benzyloxy-benzene sodium salt 30 following the general procedure. The crude product was 
purified by flash chromatography on silica gel (n-hexane/EtOAc 14:1) to give 41 as a white solid 
(15% yield). 1H-NMR (CDCl3) δ: 5.96 (s, 2H); 7.22-7.26 (m, 2H); 7.46-7.63 (m, 2H); 7.83-7.89 (m, 
2H); 7.95-7.99 (m, 2H); 8.20-8.25 (m, 1H); 8.95-8.98 (m, 1H). 
4-(3,5-Difluorobenzyloxy)benzene-1-sulfonyl chloride (42). The title compound was prepared 
from benzyloxy-benzene sodium salt 31 following the general procedure. White solid (68% yield).
1H-NMR (CDCl3) δ: 5.15 (s, 2H); 6.77-6.85 (m, 1H); 6.94-6.97 (m, 2H); 7.08-7.13 (m, 2H); 7.97-
8.02 (m, 2H). 
4-(3,5-Dibromobenzyloxy)benzene-1-sulfonyl chloride (43). The title compound was prepared 
from benzyloxy-benzene sodium salt 32 following the general procedure. Yellow oil (82% yield). 
1H-NMR (CDCl3) δ: 5.11 (s, 2H); 7.08-7.12 (m, 2H); 7.51-7.52 (m, 2H); 7.67-7.69 (m, 2H); 7.98-
8.02 (m, 2H).  
General procedure for the synthesis of carboxylic acids 44-53 and 16. To a solution of glycine 
(68.61 mg, 0.91 mmol), in H2O (0.9 mL) and dioxane (0.9 mL) containing TEA (0.25 mL, 1.828 
mmol), the appropriate sulfonyl chloride (1.83 mmol) was added. The mixture was stirred at RT 
overnight, dioxane was evaporated and the residue was treated with EtOAc, washed with HCl 1N, 
brine and with a saturated solution of NaHCO3. Aqueous basic phases were then acidified with HCl 
1N until pH=4 and the product was extracted with EtOAc. Organic layers were collected, dried over 
Na2SO4 and concentrated in vacuo. 
2-(4-(4-Bromobenzyloxy)phenylsulfonamido)acetic acid (44). The title compound was prepared 
from sulfonyl chloride 33 following the general procedure. White solid (88% yield). 1H-NMR 
(DMSO-d6) δ: 3.53 (d, J=5.86 Hz, 2H); 5.18 (s, 2H); 7.15-7.19 (m, 2H); 7.41-7.45 (m, 2H); 7.60-
7.64 (m, 2H); 7.71-7.75 (m, 2H); 7.89 (t, J=5.86 Hz, 1H). 
2-(4-(4-Fluorobenzyloxy)phenylsulfonamido)acetic acid (45). The title compound was prepared 
from sulfonyl chloride 34 following the general procedure. White solid (73% yield). 1H-NMR 
(DMSO-d6) δ: 3.53 (d, J=6.04 Hz, 2H); 5.16 (s, 2H); 7.14-7.18 (m, 2H); 7.24-7.28 (m, 2H); 7.49-
7.56 (m, 2H); 7.70-7.74 (m, 2H); 7.89 (t, J=6.04 Hz, 1H). 
2-(4-(4-(Trifluoromethoxy)benzyloxy)phenylsulfonamido)acetic acid (46). The title compound 
was prepared from sulfonyl chloride 35 following the general procedure. White solid (80% yield). 
1H-NMR (DMSO-d6) δ: 3.53 (d, J=5.67 Hz, 2H); 5.22 (s, 2H); 7.15-7.19 (m, 2H); 7.39-7.43 (m, 
2H); 7.58-7.62 (m, 2H); 7.71-7.75 (m, 2H); 7.89 (t, J=5.67 Hz, 1H). 
2-(4-(Biphenyl-4-ylmethoxy)phenylsulfonamido)acetic acid (47). The title compound was 
prepared from sulfonyl chloride 36 following the general procedure. Pinkish solid (45% yield). 1H-
NMR (DMSO-d6) δ: 3.54 (d, J=6.02 Hz, 2H); 5.24 (s, 2H); 7.18-7.22 (m, 2H); 7.37-7.57 (m, 5H); 
7.66-7.76 (m, 6H); 7.89 (t, J=6.02 Hz, 1H). 
2-(4-(3-Bromobenzyloxy)phenylsulfonamido)acetic acid (48). The title compound was prepared 
from sulfonyl chloride 37 following the general procedure. White solid (81% yield). 1H-NMR 
(DMSO-d6) δ: 3.54 (d, J=6.02 Hz, 2H); 5.19 (s, 2H); 7.16-7.20 (m, 2H); 7.33-7.58 (m, 3H); 7.68-
7.72 (m, 2H); 7.75-7.76 (m, 1H); 7.89 (t, J=6.02 Hz, 1H). 
2-(4-(3-Fluorobenzyloxy)phenylsulfonamido)acetic acid (49). The title compound was prepared 
from sulfonyl chloride 38 following the general procedure. White solid (76% yield). 1H-NMR 
(MeOD-d6) δ: 3.67 (s, 2H); 5.1 (s, 2H); 7.03-7.29 (m, 5H); 7.35-7.46 (m, 1H); 7.78-7.82 (m, 2H). 
2-(4-(3-(Trifluoromethoxy)benzyloxy)phenylsulfonamido)acetic acid (50). The title compound 
was prepared from sulfonyl chloride 39 following the general procedure. White solid (75% 
yield).1H-NMR (DMSO-d6) δ: 3.53 (d, J=6.04 Hz, 2H); 5.25 (s, 2H); 7.16-7.20 (m, 2H); 7.34-7.37 
(m, 1H); 7.49-7.60 (m, 3H); 7.71-7.75 (m, 2H); 7.89 (t, J=6.04 Hz, 1H). 
2-(4-(Biphenyl-3-ylmethoxy)phenylsulfonamido)acetic acid (51). The title compound was 
prepared from sulfonyl chloride 40 following the general procedure. White solid (60% yield). 1H-
NMR (MeOD-d6) δ: 3.64 (s, 2H); 5.17 (s, 2H); 7.15-7.19 (m, 2H); 7.29-7.48 (m, 6H); 7.58-7.65 (m, 
3H); 7.70 (s, 1H); 7.79-7.83 (m, 2H). 
2-(4-(Quinolin-8-ylmethoxy)phenylsulfonamido)acetic acid (52). The title compound was 
prepared from sulfonyl chloride 41 following the general procedure. White solid (72% yield). 1H-
NMR (Acetone-d6) δ: 3.65 (s, 2H); 5.84 (s, 2H); 7.18-7.22 (m, 2H); 7.57-7.67 (m, 2H); 7.77-7.81 
(m, 2H); 7.92-7.97 (m, 2H); 8.40-8.45 (m, 1H); 8.93-8.95 (m, 1H). 
2-(4-(3,5-Difluorobenzyloxy)phenylsulfonamido)acetic acid (53). The title compound was 
prepared from sulfonyl chloride 42 following the general procedure. White solid (81% yield). 1H-
NMR (DMSO-d6) δ: 3.53 (d, J=5.13 Hz, 2H); 5.22 (s, 2H); 7.16-7.22 (m, 5H); 7.72-7.75 (m, 2H); 
7.89 (t, J=5.13 Hz, 1H). 
2-(4-(3,5-Dibromobenzyloxy)phenylsulfonamido)acetic acid (16). The title compound was 
prepared from sulfonyl chloride 43 following the general procedure. Pale pink solid (79% yield). 
1H-NMR (DMSO-d6) δ: 3.54 (d, J=6.02 Hz, 2H); 5.20 (s, 2H); 7.16-7.20 (m, 2H); 7.70-7.71 (m, 
2H); 7.72-7.76 (m, 2H); 7.83-7.85 (m, 1H); 7.90 (t, J=6.02 Hz, 1H). 13C-NMR (CDCl3) δ: 44.58; 
69.079; 115.801; 123.521; 130.021; 130.185; 134.009; 142.275; 162.213; 170.207. 
General procedure for the synthesis of Benzyloxy-phenylsulfonamido N-(tert-
butyldimethylsilyloxy)acetamides 54-61. Carboxylates 44-46 and 49-53 (0.32 mmol) were 
suspended in dry CH2Cl2 (8.5 mL) and O-(tert-butyldimethylsilyl)hydroxylamine (47.9 mg 0.32 
mmol) and EDC (93.5 mg, 0.48 mmol) were added. After stirring at RT overnight, the mixture was 
washed with water and the organic phases were dried and evaporated in vacuo. 
2-(4-(4-Bromobenzyloxy)phenylsulfonamido)-N-(tert-butyldimethylsilyloxy)acetamide (54). 
The title compound was prepared from carboxylic acid 44 following the general procedure. The 
crude product was purified by flash chromatography (n-hexane/EtOAc 2:1) using a Isolute Flash Si 
II cartridge to give 54 as a white solid (43% yield). 1H-NMR (CDCl3) δ: 0.15 (s, 6H); 0.94 (s, 9H); 
3.57 (br s, 1H); 3.77 (br s, 1H); 5.01 (s, 2H); 5.24 (br s, 1H); 7.01-7.05 (m, 2H); 7.27-7.31 (m, 2H); 
7.51-7.55 (m, 2H); 7.77-7.81 (m, 2H); 8.43 (br s, 1H). 
N-(tert-Butyldimethylsilyloxy)-2-(4-(4-fluorobenzyloxy)phenylsulfonamido)acetamide (55). 
The title compound was prepared from carboxylic acid 45 following the general procedure. The 
crude product was purified by flash chromatography (n-hexane/EtOAc 2:1) using a Isolute Flash Si 
II cartridge to give 55 as a white solid (26% yield). 1H-NMR (CDCl3) δ: 0.15 (s, 6H); 0.94 (s, 9H); 
3.57 (br s, 1H); 3.79 (br s, 1H); 5.08 (s, 2H); 5.28 (br s, 1H); 7.02-7.14 (m, 4H); 7.37-7.43 (m, 2H); 
7.77-7.82 (m, 2H); 8.43 (br s, 1H).  
N-(tert-Butyldimethylsilyloxy)-2-(4-(4-
(trifluoromethoxy)benzyloxy)phenylsulfonamido)acetamide (56). The title compound was 
prepared from carboxylic acid 46 following the general procedure. The crude product was purified 
by flash chromatography (n-hexane/EtOAc 2:1) using a Isolute Flash Si II cartridge to give 56 as a 
white solid (52% yield). 1H-NMR (CDCl3) δ:0.15 (s, 6H); 0.94 (s, 9H); 3.58 (br s, 1H); 3.79 (br s, 
1H); 5.11 (s, 2H); 7.03-7.07 (m, 2H); 7.24-7.27 (m, 2H); 7.44-7.48 (m, 2H); 7.78-7.82 (m, 2H); 
8.41 (br s, 1H). 
N-(tert-Butyldimethylsilyloxy)-2-(4-(3-fluorobenzyloxy)phenylsulfonamido)acetamide (57). 
The title compound was prepared from carboxylic acid 49 following the general procedure. The 
crude product was purified by flash chromatography (n-hexane/EtOAc 3:1) using a Isolute Flash Si 
II cartridge to give 57 as a white solid (57% yield). 1H-NMR (CDCl3) δ:0.14 (s, 6H); 0.94 (s, 9H); 
3.57 (br s, 1H); 3.79 (br s, 1H); 5.12 (s, 2H); 5.28 (br s, 1H); 7.02-7.20 (m, 5H); 7.32-7.43 (m, 1H); 
7.77-7.82 (m, 2H), 8.53 (br s, 1H). 
N-(tert-Butyldimethylsilyloxy)-2-(4-(3-
(trifluoromethoxy)benzyloxy)phenylsulfonamido)acetamide (58). The title compound was 
prepared from carboxylic acid 50 following the general procedure. The crude product was purified 
by flash chromatography (n-hexane/EtOAc 2:1) using a Isolute Flash Si II cartridge to give 58 as a 
colorless oil (41% yield). 1H-NMR (CDCl3) δ: 0.15 (s, 6H); 0.94 (s, 9H); 3.57 (br s, 1H); 3.77 (br s, 
1H); 5.13 (s, 2H); 7.03-7.07 (m, 2H); 7.20-7.48 (m, 4H); 7.79-7.83 (m, 2H); 8.44 (brs, 1H). 
2-(4-(Biphenyl-3-ylmethoxy)phenylsulfonamido)-N-(tert-butyldimethylsilyloxy)acetamide (59). 
The title compound was prepared from carboxylic acid 51 following the general procedure. The 
crude product was purified by flash chromatography (n-hexane/EtOAc 3:1) using a Isolute Flash Si 
II cartridge to give 59 as a colorless oil (21% yield). 1H-NMR (CDCl3) δ: 0.14 (s, 6H); 0.93 (s, 9H); 
3.58 (br s, 1H); 3.78 (br s, 1H); 5.17 (s, 2H); 5.61 (br s, 1H); 7.05-7.09 (m, 2H); 7.36-7.51 (m, 5H); 
7.57-7.64 (m, 4H); 7.77-7.81 (m, 2H);8.84 (br s, 1H). 
N-(tert-Butyldimethylsilyloxy)-2-(4-(quinolin-8-ylmethoxy)phenylsulfonamido)acetamide (60). 
The title compound was prepared from carboxylic acid 52 following the general procedure. The 
crude product was purified by flash chromatography (n-hexane/EtOAc 1:1) using a Isolute Flash Si 
II cartridge to give 60 as a colorless oil (15% yield). 1H-NMR (CDCl3) δ: 0.14 (s, 6H); 0.92 (s, 9H); 
3.56 (br s, 1H); 3.80 (br s, 1H); 5.55 (br s, 1H); 5.88 (s, 2H); 7.13-7.17 (m, 2H); 7.43-7.60 (m, 2H); 
7.75-7.88 (m, 2H); 8.17-8.22 (m, 1H); 8.85 (br s, 1H); 8.92-8.95 (m, 1H). 
N-(tert-Butyldimethylsilyloxy)-2-(4-(3,5-difluorobenzyloxy)phenylsulfonamido)acetamide (61). 
The title compound was prepared from carboxylic acid 53 following the general procedure. The 
crude product was purified by flash chromatography (n-hexane/EtOAc 2:1) using a Isolute Flash Si 
II cartridge to give 61 as a white solid (53% yield). 1H-NMR (CDCl3) δ: 0.15 (s, 6H); 0.94 (s, 9H); 
3.59 (br s, 1H); 3.79 (br s, 1H); 5.10 (s, 2H); 5.23 (br s, 1H); 6.74-6.83 (m, 1H); 6.94-7.06 (m, 4H); 
7.79-7.83 (m, 2H); 8.41 (br s, 1H). 
General procedure for the synthesis of Benzyloxy-phenylsulfonamido N-(tetrahydro-2H-
pyran-2-yloxy)acetamides 62-64. Carboxylic acids 47, 48 and 16 (0.46 mmol) were dissolved in 
dry DMF (1 mL) and O-(tetrahydro-2H-pyran-2-yl)hydroxylamine (166.7 mg, 1.42 mmol), N-
methylmorpholine redistilled (0.15 mL, 1.38 mmol), HOBT (74.6 mg, 0.55 mmol), and EDC (123.5 
mg, 0.64 mmol) were added under N2 atmosphere. After stirring for 2 h, the reaction mixture was 
diluted with EtOAc and washed with water, saturated solution of NaHCO3, and brine. The organic 
phase was dried over Na2SO4, filtered and concentrated in vacuo.  
2-(4-(Biphenyl-4-ylmethoxy)phenylsulfonamido)-N-(tetrahydro-2H-pyran-2-yloxy)acetamide 
(62). The title compound was prepared from carboxylic acid 47 following the general procedure. 
The crude product was purified by flash chromatography (n-hexane/EtOAc 1:1) using a Isolute 
Flash Si II cartridge to give 62 as a colorless oil (61% yield). 1H-NMR (CDCl3) δ: 1.67-1.81 (m, 
6H); 3.62 (s, 2H); 3.81-3.99 (m, 2H); 4.81-4.92 (m, 1H); 5.16 (s, 2H); 7.06-7.10 (m, 2H); 7.36-7.51 
(m, 5H); 7.57-7.66 (m, 4H); 7.79-7.83 (m, 2H); 8.91 (br s, 1H). 
2-(4-(3-Bromobenzyloxy)phenylsulfonamido)-N-(tetrahydro-2H-pyran-2-yloxy)acetamide 
(63). The title compound was prepared from carboxylic acid 48 following the general procedure. 
The crude product was purified by flash chromatography (n-hexane/EtOAc 1:1) using a Isolute 
Flash Si II cartridge to give 63 as a colorless oil (86% yield). 1H-NMR (CDCl3) δ: 1.68-1.82 (m, 
6H); 3.62 (s, 2H); 3.75-3.93 (m, 2H); 4.81-4.89 (m, 1H); 5.08 (s, 2H); 5.40 (br s, 1H); 7.01-7.05 (m, 
2H); 7.29-7.35 (m, 2H); 7.46-7.49 (m, 1H); 7.56-7.57 (m, 1H); 7.78-7.82 (m, 2H); 9.13 (br s, 1H). 
2-(4-(3,5-Dibromobenzyloxy)phenylsulfonamido)-N-(tetrahydro-2H-pyran-2-yloxy)acetamide 
(64). The title compound was prepared from carboxylic acid 16 following the general procedure. 
The crude product was purified by flash chromatography (n-hexane/EtOAc 1:1) using a Isolute 
Flash Si II cartridge to give 64 a colorless oil (82% yield). 1H-NMR (CDCl3) δ: 1.67-1.81 (m, 6H); 
3.64 (s, 2H); 3.61-3.99 (m, 2H); 4.79-4.91 (m, 1H); 5.05 (s, 2H); 5.27 (br s, 1H); 7.01-7.05 (m, 2H); 
7.51-7.52 (m, 2H); 7.65-7.66 (m, 1H); 7.80-7.84 (m, 2H); 8.98 (br s, 1H). 
General procedure for the synthesis of Benzyloxy-phenylesulfonamido N-hydroxy acetamides 
3-5, 8-12. Silyl precursors (0.05 mmol) were dissolved in dry CH2Cl2 (0.4 mL) and TFA (0.22 mL, 
2.8 mmol) was added dropwise at 0 °C. After 5h stirring, TFA was evaporated. The crude products 
were purified by trituration with n-hexane/Et2O to give the desired hydroxamates 3-5 and 8-12. 
2-(4-(4-Bromobenzyloxy)phenylsulfonamido)-N-hydroxyacetamide (3). The title compound was 
prepared from O-silylate derivative 54 following the general procedure. White solid (85% yield). 
Mp: 135-137 °C; 1H-NMR (DMSO-d6) δ: 3.27 (d, J=5.31 Hz, 2H); 5.18 (s, 2H); 7.15-7.19 (m, 2H); 
7.41-7.45 (m, 2H); 7.59-7.63 (m, 2H); 7.71-7.75 (m, 2H); 8.86 (br s, 1H); 10.53 (br s, 1H). 13C-
NMR (DMSO-d6) δ: 43.11, 68.78, 114.98, 121.15, 128.70, 129.91, 131.38, 132.18, 135.77, 160.93, 
164.28. Elemental Analysis for C15H15BrN2O5S. Calculated: %C, 43.39; %H, 3.64; %N, 6.75; 
Found %C, 43.54; %H, 3.81; %N, 6.56. 
2-(4-(4-Fluorobenzyloxy)phenylsulfonamido)-N-hydroxyacetamide (4). The title compound was 
prepared from O-silylate derivative 55 following the general procedure. The crude product was 
purified by flash chromatography (n-hexane/EtOAc 2:3) using a Isolute Flash Si II cartridge to give 
4 as a white solid (36% yield); mp: 128-130°C; 1H-NMR (DMSO-d6) δ: 3.27 (d, J=5.9 Hz, 2H); 
5.17 (s, 2H); 7.15-7.19 (m, 2H); 7.24-7.28 (m, 2H); 7.49-7.56(m, 2H); 7.71-7.75 (m, 2H); 7.81 (t, 
J=5.9 Hz, 1H); 8.87 (br s, 1H); 10.53 (br s, 1H). 13C-NMR (DMSO-d6) δ: 40.71, 70.83, 114.61, 
115.73, 128.34, 128.75, 132.09, 136.84, 161.82, 163.74, 166.68. Elemental Analysis for 
C15H15FN2O5S. Calculated: %C, 50.84; %H, 4.27; %N, 7.91; Found %C, 50.97; %H, 4.31; %N, 
7.77. 
N-Hydroxy-2-(4-(4-(trifluoromethoxy)benzyloxy)phenylsulfonamido)acetamide (5). The title 
compound was prepared from O-silylate derivative 56 following the general procedure. White solid 
(87% yield); mp: 114-116 °C; 1H-NMR (DMSO-d6) δ: 3.28 (d, J=6.04 Hz, 2H); 5.23 (s, 2H); 7.16-
7.20 (m, 2H); 7.39-7.43 (m, 2H); 7.59-7.63 (m, 2H); 7.72-7.76 (m, 2H); 7.82 (t, J=6.04 Hz, 1H); 
8.88 (br s, 1H); 10.54 (br s, 1H). 13C-NMR (DMSO-d6) δ: 43.11, 68.65, 114.94, 121.06, 128.72, 
129.69, 132.22, 135.82, 147.90, 160.95, 164.28. Elemental Analysis for C16H15F3N2O6S. 
Calculated: %C, 45.72; %H, 3.60; %N, 6.66; Found %C, 45.83; %H, 3.81; %N, 6.30. 
2-(4-(3-Fluorobenzyloxy)phenylsulfonamido)-N-hydroxyacetamide (8). The title compound was 
prepared from O-silylate derivative 57 following the general procedure. The crude product was 
purified by flash chromatography (n-hexane/EtOAc 2:3) using a Isolute Flash Si II cartridge to give 
8 as a yellow solid (45% yield); mp: 98-100 °C; 1H-NMR (DMSO-d6) δ: 3.27 (s, 2H); 5.21 (s, 2H); 
7.16-7.20 (m, 3H); 7.29-7.32 (m, 2H); 7.41-7.51 (m, 1H); 7.72-7.76 (m, 2H); 9.04 (br s, 1H). 13C-
NMR (DMSO-d6) δ: 43.13, 68.73, 114.14, 114.57, 114.97, 123.61, 123.66, 128.70, 130.42, 130.58, 
132.22, 139.12, 139.26, 159.64, 160.90, 164.50. Elemental Analysis for C15H15FN2O5S. Calculated: 
%C, 50.84; %H, 4.27; %N, 7.91; Found %C, 50.93; %H, 4.34; %N, 7.57. 
N-Hydroxy-2-(4-(3-(trifluoromethoxy)benzyloxy)phenylsulfonamido)acetamide (9). The title 
compound was prepared from O-silylate derivative 58 following the general procedure. The crude 
product was purified by flash chromatography (CHCl3/MeOH 36:1) using a Isolute Flash Si II 
cartridge to give 9 as a white solid (42% yield); mp: 83-85 °C; 1H-NMR (DMSO-d6) δ: 3.27 (d, 
J=5.31 Hz, 2H); 5.25 (s, 2H); 7.17-7.21 (m, 2H); 7.31-7.38 (m, 1H); 7.48-7.56 (m, 3H); 7.72-7.76 
(m, 2H); 9.04 (br s, 2H). 13C-NMR (DMSO-d6) δ: 3.65, 29.07, 75.44, 80.54, 80.96, 87.20, 89.19, 
91.00, 92.77, 99.62, 108.83, 121.34, 124.67. Elemental Analysis for C16H15F3N2O6S. Calculated: 
%C, 45.72; %H, 3.60; %N, 6.66; Found %C, 45.79; %H, 3.76; %N, 6.49. 
2-(4-(Biphenyl-3-ylmethoxy)phenylsulfonamido)-N-hydroxyacetamide (10). The title compound 
was prepared from O-silylate derivative 59 following the general procedure. The crude product was 
purified by flash chromatography (n-hexane/EtOAc 2:3) using a Isolute Flash Si II cartridge to give 
10 as a foaming pink solid (50% yield); mp: 54-55 °C; 1H-NMR (DMSO-d6) δ: 3.26 (s, 2H); 5.27 
(s, 2H); 7.19-7.23 (m, 2H); 7.37-7.51 (m, 5H); 7.62-7.76 (m, 6H). 13C-NMR (DMSO-d6) δ: 43.13, 
69.58, 114.99, 126.19, 126.37, 126.68, 126.86, 127.55, 128.72, 128.92, 129.12, 132.05, 137.03, 
139.77, 140.34, 161.15, 164.26. Elemental Analysis for C21H20N2O5S. Calculated: %C, 61.15; %H, 
4.89; %N, 6.79; Found %C, 61.23; %H, 4.96; %N, 6.78. 
N-Hydroxy-2-(4-(quinolin-8-ylmethoxy)phenylsulfonamido)acetamide (11). The title compound 
was prepared from O-silylate derivative 60 following the general procedure. The crude product was 
purified by flash chromatography (CH2Cl2 /MeOH 18:1) using a Isolute Flash Si II cartridge to give 
11 as a white solid (70% yield); mp: 165-167 °C; 1H-NMR (DMSO-d6) δ: 3.29 (s, 2H); 5.82 (s, 2H); 
7.22-7.26 (m, 2H); 7.59-7.68 (m, 2H); 7.73-7.77 (m, 2H); 7.88-7.92 (m, 1H); 7.99-8.02 (m, 1H); 
8.42-8.46 (m, 1H); 8.91 (br s, 1H); 8.96-8.98 (m, 1H); 10.56 (br s, 1H). 13C-NMR (DMSO-d6) 
δ:43.14, 66.05, 114.90, 121.73, 126.30, 128.25, 128.43, 128,80, 131.99, 133.78, 136.48, 145.18, 
150.15, 161.41, 164.34. Elemental Analysis for C18H17N3O5S. Calculated: %C, 55.80; %H, 4.42; 
%N, 10.85; Found %C, 55.63; %H, 4.69; %N, 10.68. 
2-(4-(3,5-Difluorobenzyloxy)phenylsulfonamido)-N-hydroxyacetamide (12). The title 
compound was prepared from O-silylate derivative 61 following the general procedure. White solid 
(85% yield); mp: 125-127 °C; 1H-NMR (DMSO-d6) δ: 3.27 (d, J=6.04 Hz, 2H); 5.23 (s, 2H); 7.16-
7.27 (m, 5H); 7.72-7.76 (m, 2H); 7.83 (t, J=6.04 Hz, 2H); 10.54 (br s, 1H). 13C-NMR (DMSO-d6) δ: 
43.11, 68.18, 103.38, 110.33, 110.82, 114.99, 128.74, 132.42, 160.70, 164.26. Elemental Analysis 
for C15H14F2N2O5S. Calculated: %C, 48.39; %H, 3.79; % N, 7.52; Found %C, 48.66; %H, 3.91; 
%N, 7.46. 
General procedure for the synthesis of Benzyloxy-phenylesulfonamido N-hydroxy acetamides 
6, 7, 13. Protected Hydroxamates 62-64 (0.33 mmol) were dissolved in dioxane (0.6 mL) and a 
solution of HCl 4 N (5.94 mL) was added dropwise followed by MeOH (1.32 mL). After stirring 
for 30 min, the reaction was evaporated in vacuo. 
2-(4-(Biphenyl-4-ylmethoxy)phenylsulfonamido)-N-hydroxyacetamide (6). The title compound 
was prepared from the THP-protected hydroxamate 62 following the general procedure. The crude 
product was purified by flash chromatography (n-hexane/EtOAc 1:1) using a Isolute Flash Si II 
cartridge to give 6 as a white solid (39% yield). Mp: 163-165 °C;  1H-NMR (DMSO-d6) δ: 3.25 (s, 
2H); 5.23 (s, 2H); 7.18-7.22 (m, 2H); 7.33-7.57 (m, 5H); 7.66-7.76 (m, 6H); 8.97 (br s, 1H). 13C-
NMR (DMSO-d6) δ: 30.70, 69.29, 114.94, 126.61, 126.76, 127.49, 128.39, 128.70, 128.89, 132.15, 
135.46, 139.65, 139.85, 161.10. Elemental Analysis for C21H20N2O5S. Calculated: %C, 61.15; %H, 
4.89; %N, 6.79; Found %C, 61.21; %H, 4.99; %N, 6.66. 
2-(4-(3-Bromobenzyloxy)phenylsulfonamido)-N-hydroxyacetamide (7). The title compound was 
prepared from the THP-protected hydroxamate 63 following the general procedure. Hydroxamate 
7a was obtained after trituration with Et2O as a white crystalline solid (79% yield); mp: 124-125 
°C; 1H-NMR (DMSO-d6) δ: 3.28 (d, J=6.02 Hz, 2H); 5.20 (s, 2H); 7.17-7.21 (m, 2H); 7.34-7.58 (m, 
3H); 7.68-7.69 (m, 1H); 7.72-7.76 (m, 2H); 7.80-7.86 (t, J=6.02 Hz, 1H); 8.88 (br s, 1H); 10.55 (br 
s, 1H). 13C-NMR (DMSO-d6) δ: 43.10, 68.60, 114.96, 121.66, 126.68, 128.72, 130.32, 130.67, 
130.83, 132.25, 139.10, 160.89, 164.28. Elemental Analysis for C15H15BrN2O5S. Calculated: %C, 
43.39; %H, 3.64; %N, 6.75; Found %C, 43.41; %H, 3.75; %N, 6.49. 
2-(4-(3,5-Dibromobenzyloxy)phenylsulfonamido)-N-hydroxyacetamide (13). The title 
compound was prepared from the THP-protected hydroxamate 64 following the general procedure. 
Hydroxamate 13 was obtained after trituration with Et2O as a white solid (77% yield). Mp: 94-96 
°C; 1H-NMR (DMSO-d6) δ: 3.28 (d, J=6.02 Hz, 2H); 5.20 (s, 2H); 7.17-7.21 (m, 2H); 7.70-7.72 (m, 
3H); 7.76-7.77 (m, 1H); 7.80-7.86 (m, 2H); 10.55 (br s, 1H). 13C-NMR (DMSO-d6) δ: 43.11, 67.80, 
114.96, 122.50, 128.72, 129.47, 132.42, 132.87, 141.10, 160.68, 164.25. Elemental Analysis for 
C15H14Br2N2O5S. Calculated: %C, 36.46; %H, 2.86; %N, 5.67; Found %C, 36.51; %H, 2.93; %N, 
5.43. 
tert-Butyl 2-(4-(3,5-dibromobenzyloxy)phenylsulfonamido)acetate (65). To a solution of glycine 
tert-butyl ester hydrochloride (176 mg, 1.05 mmol), in H2O (1.0 mL) and dioxane (5.0 mL) 
containing TEA (0.44 mL, 3.15 mmol), sulfonyl chloride 43 (500 mg, 1.05 mmol) was added. The 
mixture was stirred at RT overnight, dioxane was evaporated and the residue was diluited with 
EtOAc and washed with H2O and brine. The organic phase was dried over Na2SO4, filtered and 
concentrated in vacuo to give a white solid (512 mg, 90% yield). 1H-NMR (CDCl3) δ: 1.34 (s, 9H); 
3.65 (d, J=5.3 Hz, 2H); 4.99 (t, J=5.4 Hz, 1H); 5.04 (s, 2H); 6.99-7.04 (m, 2H); 7.50 (m, 2H); 7.65 
(s, 1H); 7.79-7.83 (m, 2H). 
General procedure for the synthesis of tert-butyl esters 66 and 67. A solution of aryl bromide 65 
(250 mg, 0.48 mmol) in dioxane (4.8 mL)/H2O (1.0 mL) was sequentially treated under nitrogen 
with K3PO4 (306 mg, 1.4 mmol), the appropriate arylboronic acid (0.52 mmol), and Pd(PPh3)4 (22 
mg, 0.02 mmol). The resulting mixture was stirred for 1 h at 85 °C. After being cooled to RT, the 
mixture was treated with NaHCO3 and extracted with CHCl3. The combined organic extracts were 
dried over anhydrous Na2SO4, filtered, and evaporated under reduced pressure. The crude was 
purified by flash chromatography on silica gel column. 
tert-Butyl 2-(4-((5-bromo-4'-methoxybiphenyl-3-yl)methoxy)phenylsulfonamido)acetate (66). 
The title compound was prepared from 4-methoxyphenylboronic acid following the general 
procedure. Purified with n-hexane/EtOAc 7:2 (40% yield) as colorless oil. 1H-NMR (CDCl3) δ: 1.33 
(s, 9H); 3.65 (d, J=5.5 Hz, 2H); 3.85 (s, 3H); 4.96 (t, J=5.5 Hz, 1H); 5.12 (s, 2H); 6.94-7.00 (m, 
2H); 7.02-7.07 (m, 2H); 7.47-7.51 (m, 4H); 7.66 (s, 1H); 7.77-7.83 (m, 2H). 
tert-Butyl 2-(4-(3-bromo-5-(pyridin-3-yl)benzyloxy)phenylsulfonamido)acetate (67). The title 
compound was prepared from 3-pyridinylboronic acid following the general procedure. Purified 
with n-hexane/EtOAc 2:1 (36% yield) as white solid. 1H-NMR (CDCl3) δ: 1.32 (s, 9H); 3.63 (d, J= 
5.6 Hz, 2H); 5.14 (s, 2H); 5.29 (t, J=5.4 Hz, 1H); 7.02-7.06 (m, 2H); 7.39-7.71 (m, 4H); 7.78-7.83 
(m, 2H); 7.91 (dt, J1= 8 Hz, J2= 2 Hz, 1H); 8.64 (d, J=3.6 Hz, 1H); 8.84 (s, 1H). 
General Procedure for the Preparation of Carboxylic Acids 68 and 69. TFA (10.44 mmol, 0.8 
mL) was added dropwise to a stirred, ice-chilled solution of tert-butyl esters 66 and 67 (0.18 mmol) 
in freshly distilled dichloromethane (2.0 mL). The mixture was stirred under these reaction 
conditions for 5 h, and the solvent was removed in vacuo to give the corresponding carboxylic acids 
68 and 69. The crude products were purified by trituration with Et2O. 
2-(4-((5-Bromo-4'-methoxybiphenyl-3-yl)methoxy)phenylsulfonamido)acetic acid (68). The 
title compound was prepared from tert-butyl ester 66 following the general procedure. White solid 
(87% yield). 1H-NMR (CD3OD) δ: 3.65 (s, 2H); 3.82 (s, 3H); 5.12 (s, 2H); 6.93-6.97 (m, 2H); 7.03-
7.08 (m, 2H); 7.45-7.50 (m, 4H); 7.63 (s, 1H); 7.76-7.80 (m, 2H). 
3-(3-Bromo-5-((4-(N-(carboxymethyl)sulfamoyl)phenoxy)methyl)phenyl)pyridinium 2,2,2-
trifluoroacetate (69). The title compound was prepared from tert-butyl ester 67 following the 
general procedure. White solid (58% yield). 1H-NMR (DMSO-d6) δ: 3.53 (d, J=6.0 Hz, 2H); 5.26 
(s, 2H); 7.19-7.23 (m, 2H); 7.57-7.63 (m, 2H); 7.72-7.76 (m, 3H); 7.88-7.97 (m, 3H); 8.24 (d, J=7.8 
Hz, 1H); 8.67 (s, 1H); 8.98 (s, 1H). 
General Procedure for the Synthesis of Hydroxamates 17 and 18. EDC was added portionwise 
(92 mg, 0.48 mmol) to a stirred and cooled solution (0 °C) of the appropriate carboxylic acid 68, 69 
(0.19 mmol) and O-(tert-butyldimethylsilyl)hydroxylamine (113 mg, 0.77 mmol) in dry CH2Cl2 (10 
mL). After stirring at RT overnight, the mixture was washed with water and the organic phase was 
dried and evaporated in vacuo. Silyl precursors (0.12 mmol) were then dissolved in dry CH2Cl2 (2 
mL) and TFA (0.5 mL, 6.56 mmol) was added dropwise at 0 °C. After 5 h of stirring, TFA was 
evaporated. The crude products were purified by trituration with n-hexane/Et2O to give the desired 
hydroxamates 17 and 18. 
2-(4-((5-Bromo-4'-methoxybiphenyl-3-yl)methoxy)phenylsulfonamido)-N-hydroxyacetamide 
(17). The title compound was prepared from carboxylic acid 68 following the general procedure. O-
Silylate derivative was purified by flash chromatography on silica gel (n-hexane/EtOAc 1:1) to give 
a white solid (60% yield). 1H-NMR (CDCl3) δ: 0.02 (s, 6H); 0.85 (s, 9H); 3.65 (s, 2H); 3.82 (s, 3H); 
5.16 (s, 2H); 6.93-6.97 (m, 2H); 7.03-7.08 (m, 2H); 7.45-7.50 (m, 4H); 7.63 (s, 1H); 7.76-7.80 (m, 
2H); 10.39 (s, 1H). 
Hydroxamic acid 17 was obtained as white solid (87% yield) after trituration with Et2O. Mp: 175-
177 °C; 1H-NMR (CDCl3) δ: 3.52 (s, 2H); 3.85 (s, 3H); 5.31 (s, 2H); 7.02-7.08 (m, 2H); 7.20-7.25 
(m, 2H); 7.62-7.68 (m, 4H); 7.75 (s, 1H); 7.81-7.86 (m, 2H); 10.20 (br s, 1H). 13C-NMR (DMSO-
d6) δ: 42.10; 57.90; 69.30; 114.95; 122.49; 127.90; 128.72; 129.47; 130.10; 132.42; 132.87; 138.70; 
142.20; 159.15; 161.67; 165.21. Elemental Analysis for C22H21BrN2O6S. Calculated: %C, 50.68; 
%H, 4.06; %N, 5.37; Found %C, 50.75; %H, 4.19; %N, 5.29. 
3-(3-Bromo-5-((4-(N-(2-(hydroxyamino)-2-
oxoethyl)sulfamoyl)phenoxy)methyl)phenyl)pyridinium 2,2,2-trifluoroacetate (18). The title 
compound was prepared from carboxylic acid 69 following the general procedure. O-Silylate 
derivative was purified by flash chromatography on silica gel (n-hexane/EtOAc 1:1) to give a white 
solid (67% yield). 1H-NMR (DMSO-d6) δ: 0,03 (s, 6H); 0,86 (s, 9H); 5,27 (s, 2H); 7.20-7.24 (m, 
2H); 7.48-7.63 (m, 3H); 7.72-7.76 (m, 3H); 7.86-7.94 (m, 2H); 8.13 (dt, J1=8 Hz, J2=1.6 Hz, 1H); 
8.61 (dd, J1=4.7 Hz, J2=1.4 Hz, 1H); 8.92 (d, J=1.6 Hz, 1H); 10.75 (s, 1H). 
Hydroxamic acid 18 was obtained as pale yellow solid (37% yield) after a flash chromatography 
(CHCl3/MeOH 25:1) using a Isolute Flash Si II cartridge. Mp: 135 °C (dec.); 1H-NMR (DMSO-d6) 
δ: 3.28 (d, 2H); 5.27 (s, 2H); 7.20-7.24 (m, 2H); 7.47-7.54 (m, 1H); 7.72-7.94 (m, 6H); 8.13 (dt, 
J1=8 Hz, J2=1.6 Hz, 1H); 8.61 (dd, J1=4.8 Hz, J2=1.4 Hz, 1H); 8.88 (s, 1H); 8.92 (d, J=1.6 Hz, 1H). 
13C-NMR (CD3OD) δ: 44.57; 70.30; 116.37; 124.27; 125.42; 125.98; 130.33; 130.64; 131.13; 
136.54; 136.83; 141.33; 148.39; 149.49; 163.23; 167.64. Elemental Analysis for C22H19BrF3N3O7S. 
Calculated: %C, 43.58; %H, 3.16; %N, 6.93; Found %C, 43.75; %H, 3.29; %N, 6.69. 
General procedure for the synthesis of sulfonamides 70, 72 and 73. To a solution of sarcosine 
tert-butyl ester hydrochloride or H-D-Orn(Z)-OH or H-D-Orn(carbamoyl)-OH (0.59 mmol) in H2O 
(1 mL) and dioxane (1 mL) containing TEA (1.76 mmol, 0.25 mL) 4-(3,5-
dibromobenzyloxy)benzene-1-sulfonyl chloride 43 (0.59 mmol, 280mg) was added, and the 
reaction was stirred at RT overnight. Dioxane was then evaporated and the residue was taken up 
with EtOAc, washed with HCl 1N and brine. Organic layers were then dried over Na2SO4, and 
evaporated in vacuo to furnish derivatives 70, 72 and 73. 
tert-Butyl 2-(4-(3,5-dibromobenzyloxy)-N-methylphenylsulfonamido)acetate (70). The title 
compound was prepared from sarcosine tert-butyl ester hydrochloride following the general 
procedure. White solid (93% yield). 1H-NMR (CDCl3) δ: 1.40 (s, 9H); 2.89 (s, 3H); 3.88 (s, 2H); 
5.05 (s, 2H): 7.00-7.04 (m, 2H); 7.51-7.52 (m, 2H); 7.64-7.65 (m, 1H); 7.75-7.80 (m, 2H). 
(R)-5-(Benzyloxycarbonylamino)-2-(4-(3,5-dibromobenzyloxy)phenylsulfonamido)pentanoic 
acid (72). The title compound was prepared from H-D-Orn(Z)-OH following the general procedure. 
Carboxylic acid 72 was triturated with Et2O and n-hexane to yield a pink solid (62% yield). 1H-
NMR (DMSO-d6) δ: 1.21-1.58 (m, 4H); 2.81-2.96 (m, 2H); 3.57-3.67 (m, 1H); 4.99 (s, 2H); 5.21 (s, 
2H); 6.91-6.93 (m, 1H); 7.15-7.19 (m, 2H); 7.33 (s, 5H); 7.70-7.74 (m, 4H); 7.82-7.84 (m, 1H); 
7.89-8.15 (m, 1H). 
(R)-2-(4-(3,5-Dibromobenzyloxy)phenylsulfonamido)-5-ureidopentanoic acid (73). The title 
compound was prepared from H-D-Orn(carbamoyl)-OH (H-D-Cit-OH) following the general 
procedure. White solid (47% yield). 1H-NMR (DMSO-d6) δ: 1.22-1.60 (m, 4H); 2.84 (dd, J1= 5.8 
Hz, J2=6.6 Hz, 2H); 3.56-3.67 (m, 1H); 5.18 (s, 2H); 5.36 (s, 2H); 5.88 (t, J= 5.8 Hz, 1 H); 7.13-
7.17 (m, 2H); 7.69-7.73 (m, 4H); 7.83 (t, J=1.4 Hz, 1H); 8.00 (d, J=8.6 Hz,1H). 
2-(4-(3,5-Dibromobenzyloxy)-N-methylphenylsulfonamido)acetic acid (71). TFA (2.25 mL, 
29.24 mmol) was added dropwise to a stirred, ice-chilled solution of tert-butyl ester 70 (300 mg, 
0.51 mmol) in dry dichloromethane (4.0 mL). The mixture was stirred under these reaction 
conditions for 5 h and the solvent was removed in vacuo to give the carboxylic acid 71. White solid 
(253 mg, 0.51 mmol, quantitative yield). 1H-NMR (Acetone-d6) δ: 2.85 (s, 3H); 3.97 (s, 2H); 5.29 
(s, 2H); 7.21-7.25 (m, 2H); 7.73-7.74 (m, 2H); 7.75-7.76 (m, 1H); 7.80-7.84 (m, 2H). 
General procedure for the synthesis of 3,5-dibromobenzyloxy-phenylsulfonamido-N-
(tetrahydro-2H-pyran-2-yloxy)acetamides 74 and 75. Protected hydroxamates 74 and 75 were 
obtained from carboxylates 71 and 72 following the procedure previously described for 62-64. 
2-(4-(3,5-Dibromobenzyloxy)-N-methylphenylsulfonamido)-N-(tetrahydro-2H-pyran-2-
yloxy)acetamide (74). The crude product was purified by flash chromatography (n-hexane/EtOAc 
1:1) using a Isolute Flash Si II cartridge to give 74 as a white solid (39% yield). 1H-NMR (CDCl3) 
δ: 1.52-1.68 (m, 4H); 1.76-1.88 (m, 2H); 2.82 (s, 3H); 3.67 (s, 2H); 3.90-4.08 (m, 2H); 4.96-5.02 
(m, 1H); 5.07 (s, 2H); 7.05-7.09 (m, 2H); 7.52 (s, 2H); 7.66 (s, 1H); 7.74-7.79 (m, 2H); 9.13 (br s, 
1H). 
Benzyl (R)-4-(4-(3,5-dibromobenzyloxy)phenylsulfonamido)-5-oxo-5-(tetrahydro-2H-pyran-2-
yloxyamino)pentylcarbamate (75). The crude product was purified by flash chromatography (n-
hexane/EtOAc 3:2) using a Isolute Flash Si II cartridge to give 75 as a white solid (36% yield). 1H-
NMR (CDCl3) δ: 1.76-1.88 (m, 2H); 1.52-1.68 (m, 2H); 3.06-3.14 (m, 2H); 3.54-3.60 (m, 2H); 
3.74-3.82 (m, 2H); 3.98-4.02 (m, 2H); 4.35 (s, 1H); 4.95-5.12 (m, 1H); 5.01 (s, 2H); 5.09 (s, 2H); 
5.51 (d, J= 9 Hz, 1H); 6.98-7.03 (m, 2H); 7.33-7.34 (m, 5H); 7.51 (s, 2H); 7.66 (s, 1H); 7.78-7.82 
(m, 2H); 9.47 (br s, 1H).  
General procedure for the synthesis of 3,5-dibromobenzyloxy-phenylsulfonamido-N-
hydroxyacetamides 15 and 20. Hydroxamates 15 and 20 were obtained from THP-protected 
hydroxamates 74 and 75 following the procedure previously described for 6, 7 and 13. 
2-(4-(3,5-Dibromobenzyloxy)-N-methylphenylsulfonamido)-N-hydroxyacetamide (15). The 
crude product was purified by trituration with Et2O, n-hexane and acetone to give 15 as a white 
solid (55% yield); mp: 163-165 °C; 1H-NMR (DMSO-d6) δ: 2.67 (s, 3H); 3.52 (s, 2H); 5.21 (s, 2H); 
7.20-7.24 (m, 2H); 7.72 (s, 2H); 7.72-7.76 (m, 2H); 7.84 (s, 1H); 8.95 (br s, 1H); 10.65 (br s, 1H). 
13C-NMR (DMSO-d6) δ: 35.81, 50.10, 67.89, 115.18, 122.50, 129.05, 129.43, 129.52, 132.91, 
141.01, 161.15, 163.74. Elemental Analysis for C16H16Br2N2O5S. Calculated: %C, 37.82; %H, 3.17; 
%N, 5.51; Found %C, 37.93; %H, 3.19; %N, 5.47. 
(R)-Benzyl 4-(4-(3,5-dibromobenzyloxy)phenylsulfonamido)-5-(hydroxyamino)-5-
oxopentylcarbamate (20). The crude product was purified by trituration with Et2O and n-hexane to 
give 20 as a white solid (95% yield); mp: 88-90 °C; 1H-NMR (DMSO-d6) δ: 1.26-1.48 (m, 4H); 
2.84 (dd, J1= 8Hz, J2= 14Hz, 2H); 3.43-3.55 (m, 1H); 4.98 (s, 2H); 5.18 (s, 2H); 7.12-7.16 (m, 2H); 
7.22 (t, J= 8Hz, 1H); 7.33 (s, 5H); 7.68-7.72 (m, 2H); 7.70 (s, 2H); 7.88 (s, 2H); 7.90 (d, J= 8Hz, 
1H); 8.83 (br s, 1H); 10.54 (br s, 1H). 13C-NMR (DMSO-d6) δ: 25.22; 29.70; 53.08; 64.57; 67.21; 
114.24; 121.94; 127.10; 127.73; 127.90; 128.92; 132.30; 133.07; 136.56; 140.53; 155.37; 159.94; 
166.52. Elemental Analysis for C26H27Br2N3O7S. Calculated: %C, 45.56; %H, 3.97; %N, 6.13; 
Found %C, 45.71; %H, 3.99; %N, 6.26. 
tert-Butyl 4-(3,5-dibromobenzyloxy)phenylsulfonylcarbamate (76). Aqueous ammonia (30% 
solution) (0.67 mL) was added dropwise to a stirred, ice-chilled solution of sulfonyl chloride 43 (1 
g, 2.1 mmol) in acetonitrile (1.05 mL). The resulting mixture was stirred for 10 min at RT, and then 
it was diluted with water and the precipitate was filtered under vacuum. 4-(3,5-
dibromobenzyloxy)benzenesulfonamide was obtained as a white solid (900 mg, 2.11 mmol, 
quantitative yield). 1H-NMR (CDCl3) δ: 4.70 (br s, 2H); 5.10 (s, 2H); 7.01-7.05 (m, 2H); 7.51 (s, 
2H); 7.65 (s, 1H); 7.86-7.90 (m, 2H).  
4-(3,5-Dibromobenzyloxy)benzenesulfonamide (892 mg, 2.11 mmol) was then suspended in dry 
CH2Cl2 (2.65 mL) containing DMAP (25.9 mg, 0.21 mmol) and TEA (0.33 mL, 2.33 mmol). A 
solution of di-(tert-butyl)dicarbonate (531.6 mg, 2.44 mmol) in dry CH2Cl2 (3.69 mL) was added 
dropwise, and the reaction was stirred at RT overnight. The solution was concentrated in vacuo, and 
the residue was diluited with CH2Cl2 and treated with HCl 1N. The organic phase was then washed 
with water and brine, dried over Na2SO4, and evaporated. The crude product was purified by flash 
chromatography (n-hexane/EtOAc 7:1) using a Isolute Flash Si II cartridge to give 76 as a colorless 
oil (933 mg, 1.80 mmol, 84% yield). 1H-NMR (CDCl3) δ: 1.39 (s, 9H); 5.08 (s, 2H); 7.03-7.08 (m, 
2H); 7.27 (s, 1H); 7.51 (s, 2H); 7.65 (s, 1H); 7.95-7.99 (m, 2H). 
(R)-tert-Butyl 8-(4-(3,5-dibromobenzyloxy)phenylsulfonyl)-11,11-dimethyl-3,9-dioxo-1-phenyl-
2,10-dioxa-4,8-diazadodecane-7-carboxylate (78). To a solution of Boc-sulfonamide 76 (500mg, 
0.96 mmol), in dry THF (9.6 mL), alcohol 77 (197.84 mg, 0.64 mmol), triphenylphosphine (503.6 
mg, 1.92 mmol) and DIAD (0.32 mL, 1.6 mmol) were added. The mixture was stirred under Argon 
atmosphere for 4h at RT, and then it was evaporated under reduced pressure. The crude product was 
purified by flash chromatography on silica gel (n-hexane/EtOAc 4:1) to give 78 as a colorless oil 
(431 mg, 0.53 mmol, 83% yield). 1H-NMR (CDCl3) δ: 1.32 (s, 9H); 1.39 (s, 9H); 2.34-2.48 (m, 
2H); 3.18-3.27 (m, 1H); 3.51-3.65 (m, 1H); 4.95 (dd, J1=4.76 Hz, J2=4.76 Hz, 1H); 5.08 (s, 2H); 
5.11 (s, 2H); 5.45 (br s, 1H); 6.99-7.03 (m, 2H); 7.31-7.37 (m, 5H); 7.50 (d, J=1.6 Hz, 2H); 7.65 (t, 
J=1.6 Hz, 1H); 7.95-8.00 (m, 2H). 
(R)-8-(4-(3,5-Dibromobenzyloxy)phenylsulfonyl)-11,11-dimethyl-3,9-dioxo-1-phenyl-2,10-
dioxa-4,8-diazadodecane-7-carboxylic acid (79). TFA (2.29 mL, 29.67 mmol) was added 
dropwise to a stirred, ice-chilled solution of tert-butyl ester 78 (423 mg, 0.52 mmol) in dry CH2Cl2 
(4.0 mL). The mixture was stirred under these reaction conditions for 5 h and the solvent was 
removed in vacuo to give the carboxylic acid 79 as a white solid (291.4 mg, 0.44 mmol, 85% yield) 
after trituration with Et2O and n-hexane. 1H-NMR (DMSO-d6) δ: 1.56-1.67 (m, 1H); 1.68-1.80 (m, 
1H); 2.92-3.02 (m, 2H); 3.68-3.82 (m, 1H); 4.99 (s, 2H); 5.17 (s, 2H); 7.13-7.17 (m, 2H); 7.22 (t, 
J=5 Hz, 1H); 7.35 (s. 5H); 7.69 (s, 2H); 7.70-7.74 (m, 2H); 8.07 (d, J=8.9 Hz, 1H). 
(R)-Benzyl 3-(4-(3,5-dibromobenzyloxy)phenylsulfonamido)-4-(hydroxyamino)-4-
oxobutylcarbamate (19). The THP-protected hydroxamate was obtained from carboxylic acid 79 
following the procedure previously described for compounds 62-64. The crude product was purified 
by flash chromatography (n-hexane/EtOAc 1:1) using a Isolute Flash Si II cartridge to give a white 
solid (130 mg, 0.17 mmol, 44% yield). 1H-NMR (CDCl3) δ: 1.67-1.81 (m, 6H); 3.07-3.18 (m, 2H); 
3.32-3.61 (m, 2H); 3.70-3.86 (m, 2H); 4.42-4.51 (m, 1H); 4.98 (s, 2H); 5.12 (s, 2H); 5.33 (br s, 1H); 
5.75 (m, 1H); 6.91-6.95 (m, 2H); 7.36 (s, 5H); 7.49 (s, 2H); 7.65-7.69 (m, 2H); 7.73 (s, 1H); 10.10 
(br s, 1H). 
Hydroxamate 19 was obtained from its THP-protected precursor following the procedure previously 
described for compounds 6, 7 and 13. The crude product was purified by trituration with Et2O and 
n-hexane to give 19 as a white solid (97.3 mg, 0.14 mmol, 91% yield). Mp: 98-100 °C; 1H-NMR 
(DMSO-d6) δ: 1.40-1.76 (m, 2H); 2.84 (dd, J1=6.7 Hz, J2=12.8 Hz, 2H); 3.59-3.61 (m, 1H); 4.98 (s, 
2H); 5.18 (s, 2H); 7.12-7.16 (m, 2H); 7.33 (s, 5H); 7.68-7.72 (m, 2H); 7.70 (s, 2H); 7.83 (s, 1H); 
8.00 (d, J=8.6 Hz, 2H); 10.53 (br s, 1H). 13C-NMR (DMSO-d6) δ: 33.00, 37.15, 51.88, 65.23, 67.82, 
114.85, 122.50, 127.68, 128.29, 128.45, 132.87, 133.53, 137.03, 141.09, 155.78, 160.57, 166.70. 
Elemental Analysis for C25H25Br2N3O7S. Calculated: %C, 44.73; %H, 3.75; %N, 6.26. Found %C, 
44.81; %H, 3.99; %N, 6.19. 
(R)-N-(tert-Butyldimethylsilyloxy)-2-(4-(3,5-dibromobenzyloxy)phenylsulfonamido)-5-
ureidopentanamide (80). EDC was added portionwise (250 mg, 1.30 mmol) to a stirred and cooled 
solution (0 °C) of the carboxylic acid 73 (300 mg, 0.52 mmol), and O-(tert-
butyldimethylsilyl)hydroxylamine (305 mg, 2.07 mmol) in freshly distilled CH2Cl2 (13 mL). After 
stirring at RT overnight, the mixture was washed with water and the organic phase was dried and 
evaporated in vacuo. The crude was purified by flash chromatography (CHCl3/MeOH 50:1) using a 
ISOLUTE Flash Si II cartridge to afford the O-silylate derivative 80 as a white solid (296 mg, 80% 
yield). 1H-NMR (DMSO-d6) δ: 0.03 (s, 6H); 0.85 (s, 9H); 1.25-1.39 (m, 4H); 2.81 (dd, J= 6.0 Hz, 
2H); 3.53 (m, 1H); 5.18 (s, 2H); 5.37 (s, 2H); 5.87 (t, J=6.0 Hz, 1H); 7.12-7.16 (m, 2H); 7.69-7.72 
(m, 4H); 7.82 (s, 1H); 7.98 (brs, 1H); 10,72 (brs, 1H). 
(R)-2-(4-(3,5-Dibromobenzyloxy)phenylsulfonamido)-N-hydroxy-5-ureidopentanamide (21). 
TFA (1.8 mL, 23.3 mmol) was added dropwise to a stirred and ice-chilled solution of O-silylate 
derivative 80 (290 mg, 0.41 mmol) in CH2Cl2 (10 mL). The solution was stirred under these 
reaction conditions for 5 h and the solvent was removed in vacuo. The crude product was purified 
by trituration with Et2O and n-hexane to give the hydroxamate 21 as a white solid (230 mg, 94.6% 
yield). Mp: 80-82 °C; 1H-NMR (DMSO-d6) δ: 1.16-1.39 (m, 4H); 2.80 (m, 2H); 3.50 (dd, J1= 7.6 
Hz, J2= 7.6 Hz, 1H); 5.20 (s, 2H); 5.89 (brs, 1H); 7.13-7.18 (m, 2H); 7.69-7.74 (m, 4H); 7.84 (t, J= 
1.8 Hz, 1 H); 7.90 (d, J= 8.8 Hz, 1H); 10.54 (s, 1H). 13C-NMR (DMSO-d6) δ: 26.15; 30.25; 53.55; 
67.72; 114.70; 122.27; 128.30; 129.23; 132.65; 133.69; 141.01; 158.40; 160.38; 167.03. Elemental 
Analysis for C19H22Br2N4O6S. Calculated: %C, 38.40; %H, 3.73; %N, 9.43. Found: %C, 38.55; 
%H, 3.96; %N, 9.20. 
MMPs and ADAMs inhibition assays. Recombinant human MMP-14 catalytic domain was a kind 
gift of Prof. Gillian Murphy (Department of Oncology, University of Cambridge, UK). Pro-MMP-
1, pro-MMP-2, pro-MMP-9, and recombinant human ADAM-17 (PF133) were purchased from 
Calbiochem. Recombinant human ADAM-10 was purchased from R&D Systems. Pro-enzymes 
were activated immediately prior to use with p-aminophenylmercuric acetate (APMA 2 mM for 1 h 
at 37 °C for MMP-2, APMA 2 mM for 2 h at 37 °C for MMP-1 and 1 mM for 1 h at 37 °C for 
MMP-9). For assay measurements, the inhibitor stock solutions (DMSO, 10 mM) were further 
diluted in the fluorometric assay buffer (FAB: Tris 50 mM, pH = 7.5, NaCl 150 mM, CaCl2 10 mM, 
Brij-35 0.05% and DMSO 1%). Activated enzyme (final concentration 0.56 nM for MMP-2, 1.3 
nM for MMP-9, 1.0 nM for MMP-14cd, 2.0 nM for MMP-1, 5 nM for ADAM-17 and 20 nM for 
ADAM-10) and inhibitor solutions were incubated in the assay buffer for 4 h at 25 °C. ADAM-17 
was incubated for 30 min at 37 °C and ADAM-10 for 1 h at 37 °C in a different buffer at pH = 9 
(Tris 25 mM, ZnCl2 25 µM, Brij-35 0.005%). After the addition of 200 μM solution of the 
fluorogenic substrate Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH215 (Bachem) for all the 
enzymes in DMSO (final concentration 2 μM for all enzymes, 10 μM for ADAM-10), the 
hydrolysis was monitored every 15 sec for 20 min recording the increase in fluorescence (λex = 325 
nm, λem = 400 nm) with a Molecular Devices SpectraMax Gemini XS plate reader. The assays were 
performed in duplicate in a total volume of 200 μL per well in 96-well microtitre plates (Corning 
black, NBS). Control wells lack inhibitor. The MMP inhibition activity was expressed in relative 
fluorescent units (RFU). Percent of inhibition was calculated from control reactions without the 
inhibitor. IC50 was determined using the formula: vi/vo = 1/(1 + [I]/ IC50), where vi is the initial 
velocity of substrate cleavage in the presence of the inhibitor at concentration [I] and vo is the initial 
velocity in the absence of the inhibitor. Results were analyzed using SoftMax Pro software25 and 
GraFit software.26 
Cells and reagents. The human EOC cell lines SKOV3-luc (INT, Milan, Italy), A2774 (IST 
Genoa) and A2780 (ICLC Cell Bank, Genoa, Italy) were grown in RPMI 1640, with 2 mM L-
glutamine, 10% heat-inactivated fetal calf serum and 100 µg/mL penicillin-streptomycin (Lonza, 
Milan, Italy) at 37 °C in a 5% CO2 incubator. Cell lines identity was confirmed by genotyping 
through the Cell IDTM System (Promega) and the GeneMapper® software, version 4.0. 
Recombinant human EGF was from PeproTech EC (London, UK). PV was prepared by mixing 
sodium orthovanadate (0.1 M) and H2O2 (0.1 M) and was used within 20 min of preparation. 
Metalloproteinase inhibitors were dissolved in DMSO as 10 mM stock solution and stored in 
aliquots at -20 °C. 
Cell treatments and ELISA. Cells were seeded in 24-well plates and assays performed in 
duplicates. Subconfluent cultures were challenged with the indicated amounts of metalloproteinase 
inhibitors or the equivalent amount of their solvent as control. After 30 minutes PV (200 µM) or 
EGF (100 ng/mL) were added and incubation prolonged for 90 min or 18 h, respectively. 
Conditioned media were collected, centrifuged at 1000g and used undiluted for sALCAM detection 
by ELISA (DuoSet ELISA Development kit, R&D Systems). After background subtraction, data 
were expressed as the mean ± SD and analyzed by two-tailed Student’s t test. 
MTT assay. To test cell viability during treatment with the metalloproteinase inhibitors, parallel 
cultures were set up for evaluation with a microculture tetrazolium reduction assay using MTT [3-
(4,5-dimethyltiazol-2-yl)2,5-diphenyl-tetrazolium bromide; Sigma], as previously described.6  
X-ray Structures Selection for Docking Studies. The superposition of the fourteen ADAM-17 X-
ray structures available in the PDB, on the alpha-carbon atoms, reveals that the overall fold of the 
catalytic domain is well conserved, but a noteworthy flexibility of the S1’ and S2 (Tyr352-Gly363) 
loops exists. Thus, as already described in an our previous work,6 a deeper analysis based on the 
RMSD values calculated for every possible combination of alignment and on the S1’ and S2 loops 
shapes, identified five different clusters. From each identified cluster, the X-ray structure with the 
highest resolution (2I47, 3EDZ, 3EWJ, 2DDF, 2OI0) was chosen for subsequent molecular docking 
calculations.  
As regards MMP-1, -2, -9 and -14, the analysis of the available X-ray structures reveals that the 
overall fold of the catalytic domains is strictly conserved, thus for each MMP, the structure having 
the highest resolution, preferring those co-crystallized with organic or peptidic inhibitors, was 
chosen (PDB codes: 1HFC, 3AYU, 4H3X and 3MA2, respectively). 
Docking Simulations. Molecular docking of 21 into the X-ray structures of ADAM-17 (PDB 
codes: 2I47, 2FV5, 2OI0, 3EWJ, 2DDF) was carried out using the Glide 5.5 program.20 Maestro 
9.1.27 was employed as the graphical user interface, and Figure 4 representing the most probable 
binding mode of 21 was rendered by the Chimera software package.28 
Ligand and Protein Setup. The 3D structures of the ligands were generated with the Maestro 
fragment Build tool,27 then, a geometry-optimized ligand was prepared using Lig-Prep 2.3 as 
implemented in Maestro. The target proteins were prepared using the protein preparation wizard in 
Maestro 9.1. Water molecules were removed, and the resulting proteins were aligned based on the 
R-carbon trace. Hydrogen atoms were added, a +2 charge was assigned to the zinc ion in the active 
site, and the binding pocket was identified by placing a 20Å cube around the catalytic ion.  
Docking Setting. Molecular docking calculations were performed with the aid of Glide 5.5 in extra-
precision (XP)29,30 mode, using Glidescore for ligand ranking. A constraint that forced the 
interaction with the metal ion was included. The selected docking pose was further minimized using 
OPLSA2005 as force field, the PRCG methods until a gradient of 0.001 kcal/mol*Å2 and the 
implicit water model implemented in Macromodel. 
 
Supporting Information available: A table reporting the HPLC purity analysis data of the final 
products. This material is available free of charge via the Internet at http://pubs.acs.org. 
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Figure Captions. 
Figure 1. Progression of the SAR: from the hit compound 1 to the ADAM-17 selective inhibitor 21. 
Figure 2. Examples of ADAM-17 selective inhibitors. 
Figure 3. Inhibition of soluble ALCAM release. SKOV3-luc EOC cells were treated with the 
indicated amounts of compound 1 or 21 and then stimulated with pervanadate or EGF for 90 min or 
18 h, respectively. Conditioned media were then harvested and tested by ELISA for sALCAM 
levels. Data are expressed as % of control cultures treated with solvent (DMSO). Whole cell assays 
were performed and tested in duplicates. A representative experiment is shown. 
Figure 4. Binding mode of 21 (gold sticks) within the active site of ADAM-17 as resulted from 
docking calculations (PDB code 2OI0). H-bonds are depicted as dashed black lines. 
 
Table 1. In Vitro Enzymatica Activity (IC50 nM values) of glycine-like 
compounds 2-13 and the reference compound 1416. 
 
Compd R ADAM-17 MMP-1 MMP-2 MMP-9 MMP-14 
2 
 
590 27000 3.8 96 310 
3 
 
16 120000 1.2 1.4 630 
4 
 
145 32000 3.0 42 590 
5 
 
200 74000 7.5 37 7200 
6 
 
640 >500000 48 690 72000 
7 
 
104 >500000 15 60 1600 
                                                                                                                                                                  
8 
F
 
71 61000 7.8 110 940 
9 
 
280 >500000 20 76 2900 
10 
 
76 100000 41 920 1700 
11 
 
650 620000 670 29000 120000 
12 
 
82 181000 18 330 890 
13 
 
105 >500000 1750 51000 113000 
14b 
 17 28000 110 890 2900 
a
 The IC50 values are the average of three determinations with SD <10%. b Data 
from our lab. 
 
Table 2. In Vitro Enzymatic activitya (IC50 nM values) of close 
analogues of 13. 
Compd ADAM-17 MMP-1 MMP-2 MMP-14 
13  
105 >500000 1750 113000 
15  
160 >200000 1870 123000 
                                                                                                                                                                  
16  
>50000 nd 125000 nd 
17  
320 >200000 3800 170000 
18  
500 >500000 1045 21400 
a
 The IC50 values are the average of three determinations with SD <10%. 
Nd: not determined. 
 
 
Table 3. In Vitro Enzymatica Activity (IC50 nM values) of P1-substituted analogues of 13. 
 
Compd R ADAM-17 ADAM-10 MMP-1 MMP-2 MMP-9 MMP-14 
13 H 105 39000 >500000 1750 51000 113000 
19 (CH2)2NHCbz 43 8200 400000 4100 11000 104000 
20 (CH2)3NHCbz 11 300 370000 1440 4400 68000 
21 (CH2)3NHCONH2 1.9 150 >500000 240 1630 19500 
a
 The IC50 values are the average of three determinations with SD <10%.  
 
                                                                                                                                                                  
 
 
 
Table 4. Properties of Tested Compounds Calculated by QikProp 
Compd MWa QPlogPo/wb QPlogSc 
# of primary 
metabolitesd 
# H-bond 
donore 
# H-bond 
acceptorf 
20 685.4 4.03 -7.5 4 3 11 
21 594.3 0.68 -3.7 4 5 10 
 
a
 Lipinski’s rule of 5 (<500). b Log of the octanol/water partition coefficient, range 95% of drugs (-2/6.5). c 
Log of aqueous solubility S (mol/L), range 95% of drugs (-6.5/0.5). d Range 95% of drugs (1/8). e Lipinski’s 
rule of 5 (<5). f Lipinski’s rule of 5 (<10). 
 
 
 
Table 5. Selectivity profile of compound 21 in comparison with 16. 
Compd 
IC50a (nM) 
MMP-1 MMP-2 MMP-9 MMP-14 ADAM-17 ADAM-10 
1 1100 17 46 210 1.6 240 
21 >500000 240 1630 19500 1.9 150 
a
 The IC50 values are the average of three determinations with SD <10%.  
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                                  
 
 
 
 
Table 6. In vitro cellular activitya of synthesized compounds 13, 19-21 and the reference compound 
1. 
Inhibition of sALCAM release, IC50 (nM) 
 
A2774 SKOV3-luc A2780 
compd PVb EGFc PVb EGFc PVb EGFc 
13 >10000 >10000 5301 >10000 840 >10000 
19 1391 >10000 2096 9519 825 >10000 
20 274 7626 350 5641 349 10000 
21 45 651 58 4272 <10 845 
1 26 419 14 966 <10 1436 
a
 Whole cells assays were performed in duplicates. SD was generally within ± 10%. One experiment, 
representative of three, is shown. b Inhibition of pervanadate-induced sALCAM release. c Inhibition of EGF-
induced sALCAM release. 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                                  
Scheme 1. Synthesis of compounds 3-13 and 16a 
 
 
aReagents and conditions: (a) the appropriate substituted benzylbromide, NaOH, i-PrOH, 70 °C; (b) (COCl)2, 
DMF, CH2Cl2; (c) glycine, TEA, H2O, dioxane; (d) TBDMSiONH2, EDC, CH2Cl2; (e) TFA, CH2Cl2, 0 °C; 
(f) THPONH2, HOBT, NMM, EDC, DMF; (g) HCl 4N, dioxane, MeOH. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                                  
Scheme 2. Synthesis of compounds 17 and 18a 
 
a b
O
SO2Cl
Br
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BrBr
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O
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OH
O
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Br
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O
SO2
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N
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R
Br
d, e
OH
17: R= OCH3
18: R=
N
43 65 66, 67
68, 69
 
 
aReagents and conditions: (a) glycine tert-butyl ester hydrochloride, TEA, H2O, dioxane; (b) 3-
pyridinylboronic acid or 4-methoxyphenylboronic acid, Pd(PPh3)4, K3PO4, dioxane/H2O, 85 °C; (c) TFA, 
CH2Cl2, 0 °C; (d) TBDMSiONH2, EDC, CH2Cl2; (e) TFA, CH2Cl2, 0 °C.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                                  
Scheme 3. Synthesis of compounds 15 and 19-21a 
 
70 R=CH3, R1=H, R2=tBu
71 R=CH3, R1=H, R2=H
72 R=H, R1=(CH2)3NHCbz, R2=H
73 R=H, R1=(CH2)3NHCONH2, R2=H
74 R=CH3, R1=H
75 R=H, R1=(CH2)3NHCbz
78 79 19
15 R=CH3, R1=H
20 R=H, R1=(CH2)3NHCbz
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aReagents and conditions: (a) sarcosine tert-butyl ester hydrochloride or H-D-Orn(Z)-OH or H-D-
Orn(carbamoyl)-OH, TEA, H2O, dioxane; (b) TFA, CH2Cl2, 0 °C; (c) THPONH2, HOBT, NMM, EDC, 
DMF; (d) HCl 4N, dioxane, MeOH; (e) NH3 aq, CH3CN, 0°C to rt; (f) (Boc)2O, TEA, DMAP, CH2Cl2; (g) 
77, PPh3, DIAD, THF; (h) TFA, CH2Cl2, 0 °C; (i) THPONH2, HOBT, NMM, EDC, DMF; (l) HCl 4N, 
dioxane, MeOH; (m) TBDMSiONH2, EDC, CH2Cl2; (n) TFA, CH2Cl2, 0 °C. 
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